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ABBREVIATIONS 
apo apo(lipo)protein 
FCR fractional catabolic rate 
HDL high density lipoproteins (d>1.063 g/ml) 
HLP hyperlipoproteinemia 
IDL intermediate density lipoproteins (d: 1.006-1.С 19 g/ml) 
LDL low denstiy lipoproteins (d: 1.006-1.063 g/ml) 
LDL- low density lipoproteins (d: 1.019-1 .063 g/ml) 
LPL lipoprotein lipase 
η number 
no case number 
SD standard deviation 
SEM standard error of mean 
TG triglycerides 
VLDL very low density lipoproteins (ά<Ί.006 g/ml) 
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CHAPTER 1 
INTRODUCTION AND OUTLINE OF INVESTIGATIONS 
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INTRODUCTION 
Type III hyperlipoproteinemia (HLP), also known as familial 
dysbetalipoprotememia, broad-beta-disease and floating-beta-
disease, is a familial disturbance in the metabolism of lipopro­
teins. It is characterized by raised levels of serum cholesterol 
and serum triglycerides (TG), the occurrence of pathognomonic 
xanthomas in the palmar creases of the hands and of tubero-
eruptive xanthomas on the elbows, knees, buttocks and hands, 
and a strong predisposition to coronary and peripheral athero­
sclerotic vascular disease. This introduction gives a short 
survey of the present knowledge about type III HLP, especially 
referring to the pathogenesis, inheritance and diagnosis. More 
detailed reviews of this disorder and the pathophysiology of 
lipoprotein metabolism can be found in the recent literature 
(1-4). 
Cholesterol and TG are transported in the plasma in lipo­
proteins. These consist of a core of non-polar lipids, choles­
terol esters and TG, surrounded by a monolayer of more polar 
lipids, phospholipids and unestenfied cholesterol, and specific 
proteins, the apo(lipo)proteins. This monolayer makes the lipo­
protein miscible in the plasma. The lipoproteins can be sepa­
rated in ma^or classes by ultracentrifugation (chylomicrons, 
very low density lipoproteins, low density lipoproteins, high 
density lipoproteins) and by electrophoresis (α, preß and В 
lipoproteins). The dietary fat enters the plasma as chylomicrons, 
the newly synthesized endogenous TG as very low density lipopro­
teins (VLDL) . During catabolism these TG-nch particles decrease 
in size and increase in density, while TG are hydrolysed. 
In type III HLP there is an accumulation of VLDL remnants. 
These particles are intermediate products in the conversion of 
VLDL to low density lipoproteins (LDL). The VLDL contain also 
cholesterol and the apoproteins В, С and E. During circulation 
m the blood they are converted into VLDL-remnants by removal of 
TG and apoC under influence of the enzyme lipoprotein lipase. 
The remnant particles contain as much cholesterol as TG, and the 
apoproteins В and E. Some of the VLDL-remnants are directly 
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degraded in the liver but most are converted to LDL. This con-
version probably takes place also in the liver. Because TG and 
apoE are removed during this conversion, LDL contain particular-
ly cholesterol and apoB. VLDL-remnants are metabolized very 
quickly, so that they are hardly detectable m normal serum. In 
type III HLP, however, their level is increased. 
There is a continuous spectrum of VLDL-remnants throughout 
the density range of the VI,DL-fraction (d<1.006 g/ml) and the 
intermediate density lipoprotein (IDL)-fraction ( 1.006<d<1.019 
g/ml), but most are present in the VLDL-fraction. Therefore, in 
type III HLP the VLDL-fraction has a relatively high cholesterol 
moiety as the consequence of the accumulation of these choles-
terol-rich particles. The VLDL-fraction of normal subjects has 
preß mobility on electrophoresis on agarose. Because VLDL-rem-
nants have intermediate ß- preß mobility, the VLDL-fraction of 
type III patients shows two bands: one with the original preß 
mobility and one with intermediate ß- preß mobility (5). Elec-
trophoresis of total serum of these patients can display a 
"broad-ß band", or an extra band with intermediate migration. 
The pathogenesis of this disorder has not yet been fully 
elucidated. A disturbance in the catabolism of VLDL-remnants 
is likely (6). This is probably associated with the finding of 
a gross lack* of one of the isoforms of apoprotein E, apoE-3, 
in these patients (7), because the catabolism of VLDL-remnants 
occurs by interaction of these particles with apoE-receptors on 
the hepatocyte membrane (8). However, there are also indications 
for an increase in VLDL-production, leading to saturation of the 
metabolic pathway from VLDL to LDL (9). 
ApoE-3 deficiency is inherited in an autosomal recessive 
mode (7). The apoE-3 content of VLDL appears to be determined 
by two co-dominant alleles apoE and apoE . Homozygoty for apoE 
gives a normal apoE-3 level, heterozygoty an intermediate level, 
and homozygoty for apoE a gross lack or complete deficiency of 
*Recently Zannis and Breslow (J Biol Chem 1980, 255 1759-1762) 
showed with two-dimensional gel electrophoresis that an apoE-
isoprotein is not missing in this condition but merely shifted 
to a more acidic isoelectric point. 
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apoE-3. The frequency of these phenotypes in the German popula-
tion has been estimated as respectively 84, 15 and 1% (7). How-
ever, only 1 to 4% of the subjects, deficient of apoE-3, have 
raised lipid levels. Presumably, genetic and environmental 
factors contribute to the development of hyperlipidemia. 
Today, a definite diagnosis of type III hyperlipoprotein-
emia has to be based on three characteristics of the VLDL-
fraction: 
1. a gross lack, or absence of apoE-3 (7) 
2. a relatively high cholesterol content, appearing from a ratio 
between VLDL-cholesterol and serum TG (in mmol/1) of more 
than 0.69 (10) or a ratio between VLDL-cholesterol and VLDL-
TG of more than 0.9 2 (11) 
3. intermediate ß- preß mobility on electrophoresis on agarose 
(5). 
These tests require elaborate laboratory facilities. The VLDL-
fraction has to be isolated by ultracentnfugation and the iso-
forms of apoproteins E have to be determined by the technique 
of analytical isoelectric focusing. 
The eminent response to therapy makes it worth-while to 
recognize the disorder. In most cases serum lipids can be low-
ered to normal values with caloric restriction, in some cases 
after addition of the drug Clofibrate. Xanthomas disappear most-
ly in several months. 
OUTLINE OF THE INVESTIGATIONS 
Between 1956 and 1980 39 patients with type III HLP have 
been studied in our department. In most of these subjects the 
classification has been confirmed according to the modern 
criteria with advanced laboratory techniques. The clinical 
features of these patients including the presence of xanthomas 
and the atherosclerotic vascular complications are described in 
chapter 2. 
Relatives of type III patients have been screened for hyper-
lipidemia and the apoE-phenotype in order to determine the pre-
valence of HLP and the type of HLP among these subjects and to 
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investigate the relation between the prevalence of HLP, the 
composition of the lipoproteins and the apoE-phenotype (chapter 
3) . 
The short-term beneficial effect of dietary and drug treat-
ment has been well documented. In chapter 4 we describe retro-
spectively the long-term results of therapy with Clofibrate in 
9 patients during at least 7 years. 
Besides these clinical studies some metabolic investiga-
tions were performed in order to shed more light on the patho-
genesis of this disorder and on the mode of action of lipid 
lowering drugs. The first concerned a possible causal relation-
ship between the deficiency of apoE-3 and the removal defect of 
VLDL-remnants. To test this assumption the effect of infusion 
of donor plasma with a normal apoE-3 content on the lipoproteins 
m a type III patient has been studied (chapter 5). This was 
done on the analogy of such an experiment in a patient with 
massive hypertriglyceridemia, caused by deficiency of apoC-II, 
the co-factor of lipoprotein lipase. In that case, infusion of 
plasma had supplied the missing co-factor apoC-II and had led to 
a dramatic fall of serum TG (12). 
The turnover rate of VLDL-TG has been measured with the 
radioglycerol method in order to investigate whether an increase 
in VLDL-production plays a role in the pathogenesis of type III 
HLP. The validation of this measurement in type III HLP and the 
results are presented in chapter 6. 
The hypolipidemic drug Clofibrate is used in many types of 
HLP, but is most effective in type III HLP. Studies m normo-
lipidemic subjects and in patients with HLP other than type III 
revealed different kinds of mode of action. We have determined 
the turnover rate of VLDL-TG and plasma levels of several lipo-
protein fractions in type III patients before and during therapy 
with Clofibrate to study its effect on the VLDL-production and 
the catabolism of VLDL-remnants (chapter 7). In the same way the 
mode of action of estrogen has been studied, because in type III 
HLP estrogen has a hypolipidemic effect m contrast to the hyper-
lipidemic effect in normal and hypertnglyceridemic subjects 
(chapter 8). 
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CHAPTER 2 
CLINICAL FEATURES 0Γ PATIENTS WITH TYPE III 
HYPERLIPOPROTEINEMIA 
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ABSTRACT 
The clinical features of type III hyperlipoproteinemia in 
27 male and 12 female subjects (29 to 72 years of age) are 
described (including 35 probands and 4 of their relatives, 
detected by family screening). The abnormal cholesterol-rich 
composition of the very low density lipoproteins and the gross 
lack of apoprotein E-3 were the basis for diagnosis. Between 
1956 and 1975 most patients were referred because of xanthomas 
or atherosclerotic disease, whereas after 1975 the hyperlipid-
emia was discovered accidentally. The mean initial serum choles-
terol level was twice the upper normal limit, that of the serum 
triglycerides was about four times that value. The age of onset 
of the disorder m most men was between 25 and 50, in women 
after 50 years. There was a high occurrence of obesity (62%), 
tubero-eruptive and palmar xanthomas (59%), and atherosclerotic 
vascular disease (56%). Vascular disease was equally distrib-
uted about coronary and peripheral arteries, which is m strik-
ing contrast with the distribution in the population and in 
patients with type II hyperlipoproteinemia. Two of each three 
men above the age of 4 5 years and one of each two women above 
55 had atherosclerotic complications. 
The high occurrence of atherosclerotic vascular disease in 
rather young patients stresses the importance of recognition of 
the disorder because of its eminent accessibility to treatment. 
For definite classification elaborate laboratory facilities are 
needed, but the diagnosis may be suspected on the clinical 
characteristics. 
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INTRODUCTION 
Type III hyperlipoproteinemia (HLP) is a familial disease 
clinically characterised by the occurrence of xanthomas, a 
strong predisposition to cardiovascular disease (1) and an 
eminent accessibility to therapy (2). The disorder is based on 
a defect in lipoprotein metabolism. The incidence of the disease 
is low. However, the diagnosis is probably not established in 
many cases because this requires advanced laboratory investiga-
tion. 
Until now, the largest series of patients with type III HLP 
has been described in a study by Morganroth et al (3), com-
prising the clinical data of 47 patients. Besides, there are 
several other reports, including one from the Netherlands (4-7). 
The biochemical characteristics of type III have been 
defined more exactly, since the recent discovery of the lack of 
apolipoprotem E-3 m the very low density lipoproteins (VLDL) 
of these patients (8). In none of the above mentioned papers 
this diagnostic biochemical criterion has been included. 
In this study we describe the clinical features of 39 well 
defined and well documented cases of type III HLP, which have 
been diagnosed and treated in our department. The high occur-
rence of vascular disease on a rather young age in our patients 
stresses the importance of recognition of the disorder. 
PATIENTS AND METHODS 
The study concerns 27 male and 12 female patients with type 
III hyperlipoproteinemia, who have been treated in our depart-
ment between 1956 and 1980. Individual data of the patients are 
given in the appendix. Seven patients had died at the end point 
of the study in 1980. Patients, who had been detected by family 
screening, were only included, if they were treated in our 
department. In two type III patients the diagnosis of hypo-
thyroidism had been made. Although the hyperlipidemia improved 
during substitution therapy, the serum lipids remained elevated. 
Therefore, these patients have been included. 
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The diagnosis type III HLP is nowadays based on the abnor-
mal composition of the VLDL. The VLDL-fraction is relatively 
cholesterol-rich, resulting in a ratio between VLDL-cholesterol 
and serum triglycerides (TG) (expressed in mmol/1) of more than 
0.69 (9) and a ratio between VLDL-cholesterol and VLDL-TG of 
more than 0.92 (10). The VLDL have 3-inobility with electro-
phoresis on agarose (group 4 and 5 pattern according to Demacker 
(11)). One of the isoprotems of apolipoprotein E, apoE-3, is 
lacking in the VLDL (8). Most of our patients have been subjec-
ted to these diagnostic tests, but some only after they had 
been treated successfully during many years. Before these tests 
could be performed, the diagnosis was considered because of the 
xanthomas, elevated serum cholesterol with turbid serum and the 
broad-ß-band with electrophoresis of serum (12). 
In all 39 patients electrophoresis of serum and VLDL on 
agarose has been performed. One patient (no. 3) died before 
further tests could be performed. However, the diagnosis was 
supported by the severe elevation of both serum cholesterol and 
triglycerides, the occurrence of coronary and peripheral vascu-
lar disease on rather early age (52 and 57 years, respectively) 
and the well documented diagnosis of this disorder in a brother 
(patient no. 2). In 6 patients the composition of the VLDL-
apoprotein moiety was not known: in 5 cases (no. 3, 5, 11, 19, 
25) because the laboratory procedure was not yet available when 
they died and in one case (no. 19) because the patient was not 
under regular control anymore. Three of these 6 patients had 
extensive xanthomas (no. 5, 11 and 25) and two had other cases 
of the disorder among their relatives (no. 3 and 11). 
The diagnosis coronary heart disease was made if the 
patient had a typical history of angina pectoris or obvious 
electrocardiographic evidence of myocardial infarction. Definite 
peripheral vascular disease was considered to be present if the 
patient had intermittent claudication m combination with ab-
sent or decreased peripheral pulses, probable vascular disease 
if they had markedly decreased or absent peripheral pulses or 
a decreased systolic ankle pressure (13) without complaints of 
intermittent claudication. When peripheral vascular disease is 
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mentioned simply, the definite form is meant. The relative body-
weight was calculated as the quotient of the actual weight χ 
100% and the ideal weight based on the tables of the Metropoli­
tan Life Insurance Company (1959). Obesity was defined as a 
relative body-weight of more than 120%. 
The onset of the disorder type III hyperlipoproteinemia was 
arbitrarily defined as the age at which the patient had firstly 
noticed xanthomas or symptoms of vascular disease or was found 
to have hyperlipidemia. The actual age was defined as the age 
in 1980 or m the year of death. 
Blood samples were taken by venepuncture after an overnight 
fast. Depending on the time of the first visit to our department 
various methods for the determination of cholesterol were used: 
initially the FeCl^-H^SO. method (14), later an automated method 
with use of the Liebermann-Burchard reagent (15); in the most 
recent years an enzymatic method (16) was used. Triglycerides 
were initially determined with an enzymatic method (17), using 
a commercially available reagent (Boehnnger, Mannheim, FRG) . 
Later a semi-automated colorimetrie method was used (18). The 
methods for separation and determination of the lipoprotein 
fractions with ultracentnfugation and by agarose gel electro­
phoresis were described previously (11, 19). The ratio apopro­
tein E-3/E-2 in the VLDL was determined with isoelectric fo­
cusing as described previously (20). 
All data are given as mean + 1 standard deviation. For 
statistical analysis Student's t-test for unpaired observations, 
the Chi-Square test and Pearson's correlation coefficient were 
used. 
RESULTS 
In this study the clinical data are given of 39 type III 
HLP patients including 35 probands and 4 of their relatives 
detected by family screening. Data are presented about the 
source of the patients, the initial serum lipids, the occurrence 
and age of onset of clinical symptoms, the influence of the 
menopause, and the occurrence of other clinical abnormalities. 
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The individual data are mentioned in the appendix. 
Source of the patients and reason of referral 
Eighteen patients were referred to our department by their 
general practioner, 10 by a dermatologist, 3 by an internist 
and 4 by other specialists. Two patients (no. 3 and 6) appeared 
to be siblings of two known probands (no. 2 and 26). Because 
there had been no family screening at that time and the hyper-
lipidemia was not yet known m these patients, these were con-
sidered to be probands. Four of the subjects, detected by 
family screening to have type III HLP, were also treated m our 
department. 
About 50 percent of the patients had been referred because 
of complaints related to the hyperlipoproteinemia: xanthomas or 
vascular disease (table 1). In only 3 patients the hyperlipo-
proteinemia per se was the indication for referral. Many pa-
tients had been referred for other reasons; in these cases the 
hyperlipoproteinemia was discovered accidentally. 
Table 1. Reason of referral of the type III patients 
number (male/female) 
xanthomas 11 (7/4) 
coronary heart disease 4 (3/1) 
peripheral vascular disease 3 (3/0) 
elevated serum lipid levels 3 (2/1) 
family screening 4 (3/1) 
reasons, unrelated to the 14 (9/5) 
hyperlipoproteinemia 
39 (27/12) 
Until 1975 patients were referred often because of the 
sequellae of the HLP, after 1975 hyperlipidemia was discovered 
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mostly by accident (table 2). The first manifestation of the 
disorder was vascular disease in 12 patients (9 males, 3 females 
females), xanthomas m 12 (8 males, 4 females) and elevated 
serum lipid levels in 15 patients (10 males, 5 females). 
Table 2. Reason of referral of type III patients in the course 
of years 
reason of referral 
atherosclerotic other 
year vascular disease xanthomas reasons 
1956-60 2 
1961-65 1 3 1 
1966-70 3 3 4 
1971-75 3 3 4 
1976-80 12 
Serum lipids 
The given levels of serum lipids and body-weight are the 
values of the first visit, when most of the patients had not yet 
been treated. Mean serum cholesterol of all patients was twice 
the upper normal limit, mean serum triglycerides of 26 patients 
about four times that value (table 3). In 13 patients the ini-
tial serum triglycerides could not be determined because the 
laboratory method was not yet available at that time. Serum 
cholesterol ranged from 6.7 to 27.5 mmol/1 and serum trigly-
cerides from 2.9 to 25.4 mmol/1. The difference in serum lipids 
between male and female patients was not significant (table 3). 
Patients with xanthomas as the initial manifestation had a 
significantly more increased serum cholesterol than those with 
vascular disease or elevated serum lipids as the firstly noticed 
symptom (p<0.01). Also m all 23 patients, showing xanthomas 
during the whole follow-up period, serum cholesterol was signif-
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Table 3. Initial serum lipids m type III patients according to sex and initial manifestation 
of the disease 
all men women initial manifestation 
AVD X HLP 
serum cholesterol* 13.9+5.2 12.8+4.7 16.2+5.8 12.3+2.6 18.5+5.2 11.5+4.5 
(39) (27) (12) (12) (12) (15) 
serum triglycerides* 7.0+4.3 6.3+2.3 8.6+6.9 5.7+1.6 6.5+1.9 7.8+5.6 
(26) (18) (8) (7) (5) (14) 
*mean+SD in mmol/l (number) 
AVD atherosclerotic vascular disease 
X xanthomas 
HLP hyperlipidemia 
p<0.01 vs patients with AVD and HLP 
icantly higher than in the 16 patients without xanthomas (15.8+ 
5.7 and 11.1+2.6 mmol/1, p<0.005). There was also a significant 
difference in serum cholesterol between the 22 patients with 
and the 17 without atherosclerotic vascular disease (15.7+5.5 
and 11.5+3.9 mmol/1, p<0.02). Moreover, serum cholesterol in 24 
patients with obesity was significantly higher than that of 15 
patients without obesity (15.3+5.8 and 11.7+3.1 mmol/1, p<0.05). 
There was, however, no significant correlation between the 
initial relative body-weight and the initial serum cholesterol 
or serum triglycerides. Twelve patients with a mean serum cho-
lesterol of 18.7+5.7 mmol/1 appeared to have as well obesity 
as xanthomas as atherosclerotic vascular disease. Therefore, it 
is hardly possible to study independent correlations between 
serum lipids and these clinical features. 
Clinical characteristics 
The occurrence of the various clinical characteristics is 
given in tables 4 and 5. The data about body-weight concern only 
the initial visit, whereas those about xanthomas and vascular 
disease concern the whole observation period. 
More than half of the patients, and in particular the women, 
had a body-weight of more than 20 percent above the ideal body-
weight (table 4). Mean relative body-weight of all patients was 
also markedly elevated. Mean relative body-weight of women was 
significantly higher than that of men (table 4). 
Xanthomas were seen in more than half of the patients 
(table 4). The disfiguring tubero-eruptive xanthomas (fig. 1), 
localised on the elbows, knees, hands and buttocks, are easily 
noticed, mostly by the patient himself. The frequency of this 
type of xanthomas was the same as that of the palmar xanthomas 
(palmar streaks, fig. 1), the yellow-orange coloured lipid-
deposits in the palmar creases (table 4). The latter are diffi-
cult to identify in case of unfamiliarity of the observer with 
this type of lesion. The patients themselves had never noticed 
them. There were 4 patients with only palmar xanthomas. Only one 
patient had tendinous xanthomas and one other had xanthelasmas. 
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Table 4. Clinical features in type III hyperlipoproteinemia 
men 
(n=27) 
women 
(n=12) 
total 
(n=39) 
relative body-weight (RBW)* 
obesity (RBW>120%) 
12 5+14 
14 (52%) 
147+31 
10 (83%) 
II 132+23 
24 (62%) 
xanthomas 
palmar 
tubero-eruptive 
tendinous 
xanthelasma 
14 (52%) 
11 
11 
1 
1 
9(75%) 
9 
8 
0 
0 
23 (59%) 
20 
19 
1 
1 
atherosclerotic vascular 
disease 
coronary 
coronary bypass 
definite peripheral 
vascular graft 
cerebro-vascular 
16 (59%) 
12 (44%) 
2 
12 (44%) 
6 
0 
6(50%) 
3(25%) 
1 
6(58%) 
3 
1 
22(56%) 
15(38%) 
3 
18(46%) 
9 
1 
actual age (years) 52 + 10 66 + 7 H 57 + 11 
*mean+SD 
p<0.005 vs men 
age m 1980 or in year of death (mean+SD) 
Figure 1. Xanthomas in type III hyperlipoproteinemia: tubero-
eruptive xanthomas on the elbow in patient no. 20 (a) 
on the hands in patient no. 10 before (b) and after 
(c) 6 months of treatment with Clofibrate. Xanthomas 
in the palmar creases are also present, but are hard-
ly visible in black and white print. 
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Table 5. Clinical features, according to the initial manifesta­
tion in type III hyperlipoproteinemia 
initial manifestation* 
AVD X HLP total 
(n=12) (n=12) (n=15) (n=39) 
relative bodyweight (RBW) 127+13 135+24 133+28 132+23 
obesity (RBW>120%) 9 9 б 24 
xanthomas 5 12 6 23 
atherosclerotic vascular 12 8 2 22 
disease 
age of onset 47+7 51+17 50+24 49+8 
coronary 10 5 0 15 
definite peripheral 10 6 2 18 
§ 
actual age (years) 59+6 59+11 53+13 57+11 
*AVD atherosclerotic vascular disease 
X xanthomas 
HLP hyperlipidemia 
H 
mean+SD 
age in 1980 or m year of death (mean+SD) 
Half of the patients (22 out of 39) had any form of athero­
sclerotic vascular disease (table 4). The number of patients 
with definite peripheral vascular disease was slightly greater 
than that with coronary heart disease. Nine out of the 18 pa­
tients with peripheral vascular disease needed surgical treat­
ment. Three out of the 15 patients with cardiovascular disease 
got a coronary bypass. None of the patients suffered from a 
cerebro-vascular accident. In one patient a bypass operation of 
a carotid artery was performed, because of a severe stenosis 
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without neurologic symptoms. The frequency of atherosclerotic 
vascular disease is much higher when the patients with probable 
peripheral vascular disease (decreased peripheral pulses or de­
creased systolic ankle pressure without obvious intermittent 
claudication) are included: 28 out of 39 patients (72%). Two of 
each 3 men above 4 5 years and one of each two women above 55 
years had definite vascular disease. In the other patients of 
that age there was probable vascular disease (figure 2). 
There was no difference m body-weight between groups of 
patients arranged according to their initial manifestation 
(table 5). Xanthomas occurred m almost half of the patients 
with vascular disease or elevated serum lipids as initial mani­
festation. There was a high frequency of vascular disease in 
the group, presenting with xanthomas, but significantly less in 
2 
the group with hyperlipidemia as initial manifestation (χ =8.13; 
p<0.005). The mean age of onset of vascular disease was equal 
in the three groups. Most patients with vascular disease as 
initial presentation, needed vascular surgical approach (table 
5) . 
Seven patients (6 males, 1 female) died in the course of 
the observation period of this study. They reached a mean age 
of 62 years (range 53 to 67). None of them died in our hospital. 
Autopsy was not performed. Two patients died in an hospital 
elsewhere: one (no. 1) after an acute myocardial infarction, 
the other (no. 11) with an end-stage chronic heart failure 
caused by cardiovascular disease. Five patients died acutely 
at home. One (no. 25) had an abdominal aortic aneurysm and the 
clinical cause of death was its rupture. In the other four 
patients (no. 2, 3, 5 and 22), all known with coronary heart 
disease, there was no certain cause of death. 
Age of onset and age of diagnosis 
The mean age of onset of the disorder, arbitrarily defined 
as the first moment that the patient noticed xanthomas or symp­
toms of vascular disease or the first occasion on which ele­
vated lipid levels were found, was 45+11 years. The manifesta­
si 
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tion was in men earlier than in women (mean age 40+9 and 55+9 
years; p<0.001; figure 3 ) . 
The mean interval between the age of onset and the age at 
which raised serum lipids were found, was 2 years (table 6 ) . On 
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Figure 3 The age of onset of the disorder (defined as the 
moment at which the patient firstly noticed xanthomas 
or symptoms of vascular disease or was found to have 
hyperlipidemia), of xanthomas and of atherosclerotic 
vascular disease in 39 patients with type III hyper­
lipoproteinemia. 
the average 4 years later the HLP was further classified as type 
III. This classification was not possible before 1967, the year 
of the classical description by Frednckson et al (12). In the 
18 patients, in which hyperlipidemia was established before 1970, 
the mean interval between the diagnosis hyperlipidemia and the 
classification type III was 7 years; in the 21 patients, diag­
nosed after 1970, the mean interval was 1 year. 
Patients with xanthomas as first manifestation were younger 
at the moment of onset of the disorder, than patients with vas­
cular disease or hyperlipidemia as initial manifestation but 
this difference did not reach statistical significance (p=0.06) 
(table 6). If xanthomas were the initial sign, it took never­
theless on the average 5 years, before elevated serum lipids 
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Table 6. Age of diagnosis of type III hyperlipidemia (mean+SD) 
total men women initial manifestation* 
AVD X I1LP 
number 
age of onset 
age of hyper­
lipidemia 
age of type III 
actual age 
*AVD atherosclerotic vascular disease 
X xanthomas 
HLP hyperlipidemia 
p<0.001 vs men 
§ 
age in 1980 or in year of death 
were established. Because in most of these patients hyperlipid­
emia was found before 1970, the classification type III took 
once more on the average 7 years. 
During the whole observation period xanthomas were noticed 
in the 14 men mostly before the age of 50 years, in the 9 women 
mostly after that age (mean age 37+9 and 55+10 years; p<0.001; 
figure 3 ) . 
Vascular disease occurred also earlier in men than in women. 
The first symptoms, mostly angina pectoris or intermittent 
claudication, were noticed by the 16 men between the age of 30 
and 55 years and by the 6 women after the age of 50 years (mean 
age 47+6 and 56+10 years; p<0.02; figure 3 ) . The mean age of 
onset for all 22 patients was 49+8 years. There was no diffe­
rence in age of onset of coronary heart disease and peripheral 
vascular disease for all patients (respectively 51+8 and 51+9 
ye a r s ) , neither for the 11 patients with both forms of vascular 
disease (respectively 53+9 and 52+5 y e a r s ) . The age of the 
manifestation of coronary heart disease was similar in the 12 
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39 27 
45+11 40+9 
4 7+11 42+9 
51+11 46+9 
57+11 52+10 
12 12 
SS + g*1 47 + 7 
5 7 + 711 5 0 + 9 
бО + б*
1
 52 + 8 
66 + 711 59 + 6 
12 15 
39+12 47+13 
44+11 47+13 
51+12 49+12 
59+11 53+13 
men and the 3 women: respectively 51+7 and 54+14 years. However, 
the initial symptoms of peripheral vascular disease were in the 
12 men earlier than in the 6 women: respectively 47+7 and 58+7 
years (p<0.01). 
Menopause and initial manifestation 
In female type III patients the onset of the disorder was 
mostly after the menopause (table 7). The mean age of the meno-
pause was 49+4 years, whereas the mean age of onset was 55+9 
years. Only two of the 12 women had symptoms before the meno-
pause. One (no. 10) had noticed tubero-eruptive xanthomas 10 
years before the menopause; the other (no. 21) survived a myo-
cardial infarction 6 years before the menopause, but she was 
also known with a severe hypertension. 
Table 7. Menopause and the age of initial manifestation of type 
III hyperlipoproteinemia 
patient age of age of onset initial manifestation 
(no.) menopause 
6 
8 
9 
10 
15 
16 
21 
25 
29 
33 
36 
38 
48 
42 
45 
49 
53 
45 
45 
52 
52 
54 
49 
52 
53 
52 
63 
39 
54 
65 
39 
53 
59 
53 
57 
69 
hyperlipidemia 
xanthomas 
xanthomas 
xanthomas 
xanthomas 
hyperlipidemia 
coronary heart disease 
hyperlipidemia 
peripheral vascular disease 
peripheral vascular disease 
hyperlipidemia 
hyperlipidemia 
35 
Other clinical abnormalities 
Eight of the 39 patients had hypertension (diastolic values 
above 100 mm Hg). Hyperuricemia was a common feature in our 
patients, but only one patient (no. 4) had arthralgias as a 
consequence of gout. Two patients (no. 9 and 25) had hypothy­
roidism. After thyroxin replacement therapy serum lipids de­
creased but remained elevated: serum cholesterol decreased in 
patient no. 9 from 21.0 to 7.5, serum triglycerides from 8.2 to 
4.7 mmol/1. In patient no. 25 serum cholesterol fell from 24.1 
to 12.6 mmol/l. Other causes of secondary HLP such as renal and 
hepatic dysfunction and paraproteinemia, could be excluded. None 
of the patients had clinical diabetes mellitus at the moment of 
diagnosis. In 30 patients a 100 g glucose tolerance test was 
performed. In 7 cases the result was abnormal (21). Only one 
patient (no. 10) developed clinical diabetes mellitus, that 
could be treated with oral antidiabetics. In the period of un­
controlled hyperglycemia serum cholesterol rose from 10.4 to 
15.9 mmol/1 and serum triglycerides from 7.6 to 17.7 mmol/1. 
After the institution of therapy serum lipids returned to the 
initial values. In 10 patients cholelithiasis has been demon­
strated, resulting in cholecystectomy in 7 because of com­
plaints. Twenty-one patients have not been examined for gall­
stones. Conclusions about the real incidence of gallstones and 
the influence of treatment on their development can not be 
drawn from these data. 
Interrelationships 
As mentioned above serum lipids were significantly higher 
m obese patients and patients with xanthomas than in the non-
obese and in those without xanthomas. The frequency of xanthomas 
was significantly higher in obese patients than in the non-obese 
(10 out of 12 and 5 our of 15; χ =6.62; p<0.02). 
We studied whether some clinical features, that could be 
considered as atherogenic, influenced the risk of atherosclero­
tic vascular disease in our patients (table 8). It could be 
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Table 8. The occurrence of atherosclerotic vascular disease in 
subgroups of 39 patients with type III hyperlipopro­
teinemia 
patients atherosclerotic vascular disease 
number percent 
obese 16/24 67 2
 c
_ 
χ =2.6 7; p=0.10 
non-obese 6/15 40 
with xanthomas 14/23 61 2 . ._ 
' χ =0.4 5; n.s. 
without xanthomas 8/16 5 0 
S m 0 k l n g 1 7 / 2 4 7 1
 χ
2
=5.28;
 P<0.05 
non-smoking 5/15 33 
with hypertension 5/8 63 2 .
 Ί
 _ 
-'^  χ =0 .15 ; η . ε . 
without hypertension 17/31 55 
initial serum cholesterol 
above median 15/20 75 2
 Γ
 __ „ ._ 
χ =5.77; p<0.02 
below median 7/19 37 
men 16/27 59 2
 n n Q 
χ =0.09 ; n.s. 
women 6/12 50 
expected that obese patients, by having higher lipid levels, 
would show a greater tendency to atherosclerotic complications. 
Vascular disease occurred more in obese than in non-obese sub­
jects, but the difference did not reach statistical significance. 
Patients with xanthomas could also be expected to have a greater 
risk because of their higher serum lipids: however, the frequen­
cy in patients with xanthomas was not higher than in those with­
out xanthomas. Smoking habits could also influence the pre­
valence of vascular disease; indeed, smoking patients had more 
often vascular disease than non-smoking patients. Moreover, 
among patients with vascular disease as initial manifestation 
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there were significantly more smokers than among patients with 
raised serum lipids as initial manifestation (9 out of 12 and 5 
2 
out of 15; χ =4.64; p<0.05). The high occurrence of vascular 
disease among patients presenting with xanthomas (8 out of 12) 
could be related to the great number of smokers (10 out of 12). 
Hypertension did not contribute to a greater risk of athero­
sclerotic vascular disease in our patients. There were signif­
icantly more atherosclerotic complications among subjects with 
an initial serum cholesterol level above the median value in 
the whole group than among subjects with a level below the 
median. The occurrence of vascular disease was similar in men 
and women, but the actual age of women was higher than that of 
men (table 4), which could influence the frequency of vascular 
disease. The actual age of the 22 patients with vascular dis­
ease, however, did not significantly differ from that of the 
17 without vascular disease (58+9 and 54+14 years). 
DISCUSSION 
In this study a description of the clinical features of 39 
patients with type III HLP is given. Other series were described 
from Bethesda (USA) (3), Seattle (USA) (4), London (UK) (5), 
Hamilton (Canada) (6) and Leiden (The Netherlands) (7). Most of 
these studies came from departments of medicine. However, the 
British and Dutch series were from departments of dermatology. 
Of course, the selection of patients gives differences in the 
frequency of some clinical features in the several studies. A 
survey of the most important clinical symptoms in these studies 
and in our study is given in table 9. For comparison, data from 
an earlier study from our department (22), concerning 35 pa­
tients with severe type II HLP, are added to this table. 
Advances in biochemistry during the last decades have per­
mitted the differentiation of type III HLP from other types of 
HLP. Description of familial hyperlipidemias dates back to 100 
years ago, when the xanthomas drew attention (1). Thirty years 
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Table 9. Summary of c l i n i c a l and chemical c h a r a c t e r i s t i c s of s e r i e s of sub­
j e c t s with type I I I hyperl ipoproteinemia (HLP) and one study of 
subjects with type I I HLP 
number of subjects 
male/female 
age range (yrs) 
mean cholesterol (mmol/l) 
mean triglycerides (mmol/l) 
xanthomas 
palmar 
tuberous, tubero-eruptive 
tendinous 
xanthelasma 
coronary heart dispase 
peripheral vascular diasese 
cerebro vascular disease 
clinical diabetes mellitus 
hypothyroidism 
gout 
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ago l i p o p r o t e i n f r a c t i o n s could be i s o l a t e d by u l t r a c e n t r i f l i g a ­
t i o n . I t was d e m o n s t r a t e d t h a t t h e compos i t ion of t h e s e f r a c ­
t i o n s in p a t i e n t s w i t h t e n d i n o u s xanthomas ( type I I HLP) d i f -
39 
fered from that in patients with tubero-eruptive xanthomas (type 
III HLP) (23). In 1967 Fredrickson et al (12) gave their classi-
cal description of the pathophysiology of lipid transport and 
type III HLP was defined as a separate entity. The diagnosis had 
to be confirmed biochemically by the presence of floating ß-
lipoprotems (VLDL with ß-mobility) and a broad-ß-lipoprotem 
band on electrophoresis. However, demonstration of these charac-
teristics requires ultracentrifugation and a meticulous electro-
phoretic technique and is time consuming, subjective and not 
fail-safe. Later on, the abnormal cholesterol-nchdom of the 
VLDL became a cornerstone in diagnosis (9, 10). Recently, the 
lack of one of the isoforms of apolipoprotem E, apoE-3, was 
demonstrated by analytical isoelectric focusing of VLDL (8). 
Nowadays, the diagnosis of type III HLP is based on the combi-
nation of the deficiency of apoE-3 in VLDL, a high cholesterol 
content of VLDL and the presence of floating ß-lipoproteins. 
Most of our patients have been classified according to 
these criteria. Many were tested only after successful treat-
ment. However, it is known that the VLDL of type III patients 
with normal serum lipids during treatment still have 0-mobility 
on electrophoresis (24), remain rich in cholesterol (9) and 
still are lacking apoE-3 (25). In some of our patients no apo-
protein analysis has been done, and m one patient the choles-
terol content of VLDL has not been determined. Nevertheless, 
the classification type III HLP in these patients could be 
sufficiently supported by the clinical picture and by family 
studies. In none of the above mentioned studies from the litera-
ture the apoprotein composition of VLDL has been included in the 
diagnostic criteria. 
The mean age, at which the diagnosis type III HLP was made 
in our patients, was 51 years, on the average 4 years after 
raised serum lipids has been found for the first time. This 
interval was caused by the unfamiliarity with the disorder be-
fore the date of the initial description of type III HLP and 
the difficulty of the laboratory tests. In the last decennium 
the lag period was on the average one year reflecting the im-
provement in knowledge and laboratory potential. The time-course 
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between the onset of the disorder and the finding of elevated 
serum lipids has been caused by both doctor's and patient's 
delay. In patients with xanthomas as the initial manifestation 
the mean interval was 5 years, in patients with vascular disease 
3 years. In particular this long lapse of time after the mani-
festation of xanthomas is remarkable and illustrates the un-
acquaintandness of many doctors with these lesions. 
Type III HLP is a disorder, commonly expressing itself in 
adult age. There are reports about 8 cases in childhood; all 
these were in their second decade (4, 5, 26-29). Only in one 
of these studies the diagnosis was confirmed by apoE-phenotyping 
(27). In our series the youngest patient was 29 years at the 
moment of diagnosis. Another patient had noticed for the first 
time xanthomas at the age of 26 years; the diagnosis was made 
10 years later. From these data it can be concluded that expres-
sion in childhood is rare in contrast with familial hypercholes-
terolemia (type II HLP). 
In all the published series the number of men exceeds that 
of women (table 8). The expression of the disorder in women 
occurs mainly after the menopause, m contrast to familial 
hypercholesterolemia (type II HLP) and endogenous hypertrigly-
ceridemia. This seems to be the consequence of the paradoxically 
hypolipidemic effect of estrogen in type III patients (30, 31) . 
One female patient in our series, however, had noticed xanthomas 
10 years before the menopause. Although women are exposed to the 
HLP for shorter periods than male patients, the frequency of 
atherosclerotic complications appeared to be equal in male and 
female patients. This is in agreement with the data in other 
studies (3, 4). This phenomenon may, however, be related to the 
higher age of the female group. 
There was a high frequency of obesity in type III patients, 
especially among the women. No significant correlation existed 
between initial body-weight and the initial serum lipids. Mean 
serum cholesterol of the obese patients, however, was higher 
than in the non-obese. On the other hand, m the individual 
patient, a decline or rise in body-weight gives a parallel 
change in serum lipids (4). Increase of serum lipids can also 
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be induced by changes in the composition of the diet, excess of 
carbohydrate or etnanol (4, 32, 33). Therefore, a strong varia-
bility in serum lipids is a typical feature of type III patients. 
This variability interferes with attempts to find correlations 
between serum lipid levels and other features of the disorder. 
Xanthomas are the most easily identifiable clinical phenom-
enon in type III HLP. If xanthomas are present, especially the 
tubero-eruptive, the diagnosis will be made at a younger age. 
Xanthomas were noticed in more than half of our patients. The 
frequency m our series is similar to that in other studies 
from departments of medicine, but less than in those from de-
partments of dermatology (table 8), obviously, a matter of 
selection. Palmar xanthomas, xanthochromia striata palmans or 
palmar streaks, the yellow-orange lipid deposits in the palmar 
creases, were firstly described by Polano (34). They are patho-
gnomonic for type III HLP (3). Rarely they aie seen in patients 
with obstructive biliary disease and dysglobulinemia (35). The 
frequency of palmar xanthomas in our patients has probably been 
underestimated because these discrete lesions may not have been 
recognized in the early years, whereas they could have dis-
appeared later in successfully treated patients. None of the 
patients has noticed this type of xanthomas themselves. In con-
trast, the tubero-eruptive xanthomas, localised on the elbows, 
knees, buttocks and hands, are disfiguring and sometimes dis-
abling. Tendinous xanthomas and xanthelasmas are rarely seen 
in type III patients which is in striking contrast with their 
occurrence in type II HLP (table 9). Mostly, during treatment 
of the HLP the xanthomas disappear within several months (3, 25, 
36) . 
Until 10 years ago xanthomas often were the initial mani-
festation of the disorder. At present, however, the disorder is 
usually discovered accidentally by the finding of increased 
serum lipids. This may be attributed to the extensive laboratory 
screening, which has become common practice, and to the growing 
interest in hyperlipidemia. Besides, there is a decline in the 
occurrence of xanthomas in the last decennium. A possible expla-
nation could be a decline in body-weight m the course of years, 
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because obesity was accompanied by higher serum lipids and more 
xanthomas in our patients. There was indeed a tendency to de-
creasing initial serum lipids during the years but not to de-
creasing body-weight. Possibly other factors as changed diet 
habits caused the decline in serum lipids. Thus, the occurrence 
of xanthomas seems to be mainly influenced by the level of serum 
lipids and not by the body-weight. Because the presence of xan-
thomas leads to earlier recognition of the disorder at a younger 
age, the duration of exposure to hyperlipidemia probably does 
not influence the expression of xanthomas. 
It is difficult to estimate the risk of development of 
atherosclerotic vascular disease in type III patients. The fre-
quency in a group of patients depends of the reason of referral 
and the age of the patients at the moment of evaluation. Tn our 
series one third of the patients had been referred because of 
atherosclerotic vascular disease. However, a strong tendency to 
atherosclerosis appears from the fact that vascular disease 
developed in 10 out of 27 patients, in whom the presenting 
symptoms had been unrelated to atherosclerosis. The mean age 
of our patients at the end-point of the study was 57 years. By 
then, half of our patients had any form of vascular disease. 
In general, clinical symptoms of atherosclerotic vascular dis-
ease occur from the age of 45 years on in men and from that of 
55 on in women. The occurrence of vascular disease m our study 
is slightly higher than m previous reports (table 9). However, 
m most papers it is not clear whether the occurrence concerns 
the moment of diagnosis or includes the period of follow-up. 
The equal distribution of atherosclerotic vascular disease 
about coronary and peripheral arteries in type Til HLP is in 
contrast with familial hypercholesterolemia (type II HLP), a 
disorder with a strong predisposition for coronary heart dis-
ease alone. In 35 patients from our department with the latter 
disorder only one case of peripheral vascular disease has been 
noticed (22) (table 9). This is in agreement with previous 
reports (3). Cerebrovascular disease is rare in both types of 
HLP. The Framingham study has shown that in the general popula-
tion the number of subjects with clinical manifestations of 
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coronary heart disease is about seven fold that of subjects with 
peripheral vascular disease or that of subjects with cerebro-
vascular disease (37). This striking difference in the distrib-
ution of the atherosclerotic lesions within the arterial system 
between these groups is fascinating and as yet an unexplained 
enigma. 
In our series smoking appears to raise the risk of the 
development of vascular disease. In the group of patients, pre-
senting with xanthomas, there was also a high occurrence of 
vascular disease, in contrast to the group presenting with 
raised serum lipids only. This may be explained by the higher 
serum lipids and the greater number of smoking patients in the 
xanthoma group. 
Hyperlipoproteinemia can be secondary to other disorders. 
Type III HLP has been described in patients with hypothyroidism 
(38), systemic lupus erythematosus (39) and diabetic ketoacido-
sis (39). Two patients m our series had hypothyroidism. During 
replacement therapy the hyperlipidemia and the biochemical 
characteristics of type III remained, although in a less degree 
than before. Therefore, these patients were still classified as 
primary type III HLP. There was no case of clinical diabetes 
mellitus among our patients at the moment of diagnosis. In a 
small number the glucose tolerance was impaired which could be 
expected in a group of overweight middle-aged subjects. One 
patient developed clinical diabetes mellitus during the follow-
up with a temporary increase of the serum lipids. This is in 
agreement with the theory of Utermann et al (27) according to 
which the deficiency of apoprotein E-3 leads to a removal de-
fect of VLDL-remnants, mostly without hyperlipidemia, whereas 
the combination with an enhanced production of VLDL, as in 
obesity (40), hypothyroidism (41) and hyperglycemia (42), in-
duces type III HLP. 
Hyperuricemia is frequently seen in hyperlipidemic patients. 
Only one of our patients with hyperuricemia had gouty arthral-
gias. There is a high occurrence of gallstones in hypertrigly-
ceridemic patients, as a consequence of supersaturation of 
cholesterol m bile (43). Treatment with a calorie-restricted 
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diet and treatment with Clofibrate had the same lithogenic 
effect. Indeed, many of our patients have gallstones. The real 
incidence is unknown because oral cholecystograms have not been 
made in all patients. 
Recognition of type III HLP is important because of the 
high risk of atherosclerotic vascular disease and the familial 
occurrence, necessitating family screening. Case finding is 
worth-while because of the exceptionally good response to ther-
apy. Diet, mostly only caloric restriction, and sometimes addi-
tion of the drug Clofibrate normalizes serum lipids in most 
patients on the short-term (2, 3, 25) and also on the long run, 
as we have demonstrated (36). Xanthomas disappear completely in 
most patients. Only one study (44) reported an increase of peri-
pheral arterial blood flow during therapy in type III HLP pa-
tients . 
Definite classification of type III HLP requires elaborate 
laboratory facilities. However, the diagnosis may be suspected 
on clinical grounds: the elevation of cholesterol as well as 
triglycerides in combination with peripheral vascular disease, 
palmar or tubero-eruptive xanthomas or a striking variability 
in serum lipid levels. 
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APPENDIX: Clinical and biochemical characteristics of 39 patients 
initial manifestation* 
, _ clinical characteristics 
initial case sex age of meno-
manifes- no. onset diag- pause xanthomas ASCVD (age) 
tation nosis Ρ TE TD age CHD PVD CVD 
(years) 
ASCVD 1 
2 
3 
7 
13 
20 
21 
22 
26 
29 
33 
37 
M 
M 
M 
M 
M 
M 
F 
M 
M 
F 
F 
M 
56 
40 
52 
46 
41 
51 
39 
44 
39 
59 
53 
46 
62 
50 
58 
52 
44 
56 
47 
45 
43 
67 
58 
46 
xantho­
mas 
5 
8 
9 
10 
11 
12 
14 
15 
17 
18 
23 
28 
M 
F 
Γ 
F 
M 
M 
M 
F 
M 
M 
M 
M 
46 
52 
63 
39 
32 
29 
32 
54 
26 
34 
30 
35 
66 
54 
74 
57 
51 
43 
36 
56 
47 
36 
38 
51 
52 - -
54 + + 
55 
44 
40 
57 
60 
40 
52 
53 
41 
61 
39 
49 
-
66 
-
56 
48 
57 
46 
-
51 
51 
44 
39 
59 
53 
- + 
45 + + - 44 39 51 57 
+ + 
+ - - 46 46 
+ + - 46 60 52 
42 + + - 52 
45 + + - 71 -
49 + + - 39 57 53 
+ + - 32 51 51 
+ + - 29 49 
- + + 32 45 
53 + + - 54 - 64 
+ + - 26 - 52 
+ + - 34 
+ + - 30 - 33 
- + - 35 
^ist of abbreviations at the end of the appendix on page 52 
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with type III hyperlipoproteinemia, arranged according to their 
relative biochemical characteristics 
-wei 
(%) 
124 
104 
124 
117 
116 
149 
125 
134 
126 
122 
151 
127 
ght chol TG 
(mmol/1) 
11.6 
11.9 
12.3 
9.1 
10.6 
14.3 
17.2 
10.8 
17.0 
11.2 
9.2 
12.3 
3.9 
•> 
8.7 
4.3 
-> 
? 
7 
5.7 
7 
5.6 
6.4 
5.2 
ß-VLDL 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
VLDL-
ratio 
+ 
+ 
ρ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
apoE-D 
7 
+ 
7 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
remai-ks 
sibling no. 
sibling no. 
sibling no. 
sibling no. 
sibling no. 
cousin no. 
3 
2 
35 
16 
6 
27 
153 
136 
204 
126 
124 
124 
118 
142 
137 
119 
114 
125 
16.5 
16.6 
21.0 
27.5 
21.6 
22.7 
14.6 
15.2 
26.4 
13.3 
15.3 
11.1 
7 
7.2 
8.2 
7 
7.4 
7 
7 
7 
7 
6.6 
3.3 
7 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
7 
+ 
+ 
+ 
7 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
hypothyroid 
sibling no. 31 
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APPENDIX (continued) 
. . , . ., _ clinical characteristics 
initial case sex age of meno-
manifes- no. onset diag- pause xanthomas ASCVD (age) 
tation nosis Ρ TE TD age CHD PVD CVD 
(years) 
HLP 4 
6 
16 
19 
24 
25 
27 
30 
31 
32 
34 
35 
36 
38 
39 
M 
F 
F 
M 
M 
F 
M 
M 
M 
M 
M 
M 
F 
F 
M 
39 
53 
65 
57 
31 
53 
27 
45 
30 
50 
41 
50 
57 
69 
31 
41 
54 
65 
57 
35 
61 
29 
45 
37 
50 
47 
50 
57 
72 
33 
48 + + - 53 -
45 - - - -
- 33 
52 + + - 60 - 67 
+ + - 30 
+ - - 47 
49 - - -
52 + - - 69 
+ - - 31 
Abbreviations : 
Xanthomas Ρ: palmar, TE: tubero-eruptive, TD: tendinous 
ASCVD: atherosclerotic cardiovascular disease 
CHD: coronary heart disease 
PVD: peripheral vascular disease 
CVD: cerebrovascular disease 
chol: serum cholesterol, TG: serum triglycerides 
VLDL-ratio: ratio between VLDL-cholesterol and serum- or VLDL-
triglycerides above 0.69 and 0.92, respectively 
apoE-D: apolipoprotein Ε-D phenotype 
+ present, - absent, ? not determined 
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relative biochemical characteristics 
body-weight chol TG ß-VLDL VLDL- apoE-D remarks 
(%) (mmol/1) ratio 
128 8.4 7.1 + + + gout 
175 11.3 5.0 + + + sibling no. 26 
118 14.5 7.2 + + + sibling no. 21 
116 10.2 4.7 + + ? 
110 14.2 8.7 + + + 
147 24.1 ? + + ? hypothyroid 
169 8.8 7.9 + + + cousin no. 37 
111 9.43.4 + + + 
 
 
 
 
 
 
 
. 
6 . 
1 0 , 
1 0 , 
7 , 
1 7 . 
9 . 
1 0 . 
.
.  
.  
.  
.  
. 1 
.
4 
. 7 
. 1 
. 1 
. 4 
. 6 
. 3 
.4 
.  
 
.  
.  
 
? 
.  
3 .  
6 . 9 
7 . 9 
6 . 5 
2 . 9 
2 5 . 4 
3 . 7 
1 1 . 8 
 
 
 
 
 
 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
120 + + + sibling no. 11 
118 0 1 7 . + + 
138 . + + 
118 .  + + sibling no. 13 
113  + + 
202  + + 
114  + + 
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CHAPTER 3 
SERUM LIPIDS, LIPOPROTEINS AND APOLIPOPROTEIN E PHENOTYPES 
IN RELATIVES OF PATIENTS WITH TYPE III HYPERLIPOPROTEINEMIA 
ABSTRACT 
The apolipoprotein (аро)Е-З content of very low density 
lipoproteins (VLDL) is determined by two autosomal co-dominant 
alleles. Three phenotypes can be distinguished: apoE-D (defi­
ciency of apoE-3), apoE-ND (intermediate level of apoE-3), and 
apoE-N (normal apoE-3 level) (Utermann et al, Nature, 1977; 269: 
604-607) . We studied 108 (93 first-degree) relatives of 20 apo 
E-3 deficient probands with type III hyperlipoproteinemia (HLP) 
in order to determine the relation between the occurrence of HLP 
and the several apoE-phenotypes and to establish the lipoprotein 
composition m subjects with these phenotypes. 
Hyperlipidemia was found m 48 of the 108 relatives (5 type 
II, 8 type III and 35 type IV). Seven of the new type III cases 
were found among siblings, one in a cousin. In 80 relatives the 
apoE-phenotype was determined: 22 had apoE-N, 45 apoE-ND and 13 
apoE-D. The mode of inheritance of apoE-3 deficiency was in 
agreement with previous reports. The percentage of hyperlipid-
emics among subjects with phenotype apoE-N was 45%, with apoE-ND 
44% and with apoE-D 62%. All hyperlipidemic apoE-D subjects had 
type III HLP. The normolipidemic apoE-D subjects had a relative­
ly high cholesterol content of VLDL and a low LDL-cholesterol 
level, indicating a defective conversion of VLDL-remnants to 
LDL. The lipid composition of VLDL of normolipidemic subjects 
with phenotype apoE-N and apoE-ND did not differ significantly. 
It is concluded that the occurrence of HLP among relatives 
of type III patients is high and does not seem to be related to 
the apoE-phenotype, which points to a familial tendency to HLP. 
Screening of relatives of type III patients above the age of 30 
is recommended in order to find patients with HLP and subjects 
with phenotype apoE-D, at risk for the development of type III 
HLP and vascular disease. 
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INTRODUCTION 
Type III hyperlipoproteinemia (HLP) is a disorder in lipo-
protein metabolism with familial occurrence (1). Among relatives 
there are cases of type III HLP, but also of other types of HLP 
(2-5). Until recently, the discrimination between the various 
types of HLP was the greatest difficulty in family studies. 
Therefore, opinions differed about the mode of inheritance of 
type III HLP. It was thought to be autosomal dominant with var-
ying expression (2-4) or autosomal recessive (6) or polygenic 
(7). The recent discovery of the gross lack or complete defi-
ciency of apoprotein E-3 (apoE-3) in the very low density lipo-
proteins (VLDL) of type III HLP patients gave the solution in 
this respect (5, 8, 9). The apoE-3 content of VLDL appears to 
be determined by two autosomal co-dominant alleles. By measuring 
the apoE-3 content the opportunity was obtained to determine the 
heterozygous state, which was the weak point in previous studies. 
People with a normal apoE-3 content are homozygous for allei 
apoE (phenotype apoE-N), those with a gross lack or complete 
deficiency of apoE-3 are homozygous for allei apoE (phenotype 
apoE-D). People with the heterozygous genotype E E have an 
intermediate level of apoE-3 (phenotype apoE-ND). These original 
observations of Utermann et al have been confirmed in several 
other centres (10-12). In the German and North American popula-
tions about 1% has phenotype apoE-D and about 15% phenotype apo 
E-ND (9, 12). The rather high frequency of the heterozygous 
phenotype explains the vertical transmission of the homozygous 
deficient apoE-3 state in certain pedigrees, misinterpreted as 
an autosomal dominant mode of inheritance (3, 13). 
Apoprotein E is involved in the catabolism of VLDL-remnants 
by the liver through interaction with apoE-receptors on the 
hepatocyte membrane and it is suggested that deficiency of apo 
E-3 is the basic disturbance in type III HLP, leading to the 
removal defect of VLDL-remnants (14). However, only 1 to 4% of 
the people with phenotype apoE-D have HLP (5). Utermann et al 
(5) postulated that other genetic factors contribute to the 
development of HLP because the occurrence of HLP was high among 
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relatives of type III HLP patients, but low among those of sub-
jects with phenotype apoE-D without HLP. An elevated production 
of VLDL which also plays a role in the pathogenesis of familial 
HLP (15) could be that factor. Acquired factors increasing the 
VLDL-production such as an excessive intake of calories or etha-
nol could have the same effect (16) . 
The consequences of phenotype apoE-ND for lipoprotein 
metabolism are not yet clear. There is some evidence for an 
increased occurrence of HLP (5, 17) and for an abnormal choles-
terol nchdom of VLDL (13, 18) among people with this phenotype. 
The aim of this study was to determine the occurrence of 
HLP and its well defined subtypes among relatives of type III 
HLP patients and to investigate the relation between apoE pheno-
types, the occurrence of HLP and lipoprotein lipid composition 
among these people. It will be shown that there is a high fre-
quency of HLP, especially type IV, and in a less degree type III 
and type II, among these relatives. It will be demonstrated that 
among individuals with phenotype apoE-ND there is no increased 
occurrence of HLP and no alteration of lipoprotein composition 
in comparison with subjects with phenotype apoE-N. 
MATERIALS AND METHODS 
The study concerns 108 family members of 20 probands with 
type III HLP. The clinical and biochemical features of these 
patients have been described in chapter 2 (patient nos. 5, 8-11, 
13, 14, 17, 18, 20, 21, 23, 24, 27, 29, 32, 34, 37-39). Patient 
no. 37, a cousin of patient no. 27, was detected to have type 
III HLP with family screening. He was considered to be a pro-
band in the study of first-degree relatives. In most probands 
the diagnosis type III HLP was based on three abnormal charac-
teristics of the VLDL: a) the gross lack or absence of apoE-3 
in the VLDL (not examined in patient nos. 5 and 11) (9) b) the 
cholesterol nchdom of the VLDL, expressing in a ratio VLDL-
cholesterol/serum triglycerides (TG) (in mmol/1) of more than 
0.69 (19) and in a ratio VLDL-cholesterol/VLDL-TG of more than 
0.92 (20), c) the ß-mobility of VLDL on electrophoresis on 
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agarose ( 21 ) . 
Between 1977 and 1980 93 of the 104 living first-degree 
relatives (6 parents, 59 siblings, 29 children) older than 10 
years have been studied. Also 15 second- and third-degree rela-
tives participated. Most subjects came to our outpatient cl:nic 
and blood was taken by venepuncture after an overnight fast. 
Some members, living far from our department, were sent blood 
sampling tubes with instructions to have their blood drawn by 
their physician and mailed to our laboratory. 
In all individuals cholesterol in total serum, VLDL, LDL 
and HDL and TG in total serum and VLDL were determined. Electro-
phoresis on agarose of serum and VLDL was not routinely done. In 
80 subjects isoelectric focusing of VLDL was performed and the 
apoE-3/E-2 ratio determined. Neither with this procedure nor 
with a radioimmunoassay it is possible to determine the absolute 
apoE-3 content. Therefore, the ratio between apoprotein E-3 and 
E-2 is used (8). In 23 subjects this procedure could not be per-
formed because it was not yet available, in 2 subjects the pro-
cedure failed, and in 3 there was insufficient serum. 
Subjects were considered to have hyperlipidemia, if serum 
cholesterol was above 7.3 mmol/l and/or serum TG were above 2.0 
mmol/1 (under the age of 40 years above 1.8 mmol/l). 
HLP was classified as type IIa when serum cholesterol was 
above 7.3 mmol/l, LDL-cholesterol above 5.2 and serum TG were 
normal; as type lib, when serum cholesterol was above 7.3, LDL-
cholesterol above 5.2, and serum TG above 2.0; as type III, when 
serum cholesterol was above 7.3 and/or serum TG were above 2.0 
mmol/l, in combination with phenotype apoE-D; as type IV when 
LDL-cholesterol was below 5.2 and serum TG were above 2.0, under 
the age of 40 years above 1.8 mmol/l. 
Cholesterol was determined by an enzymatic method (22) and 
triglycerides by a semi-automated colorimetrie method (23). The 
methods for separation and determination of lipoproteins with 
ultracentrifugation and precipitation and the method for elec-
trophoresis on agarose have been described previously (21, 24). 
Analytical isoelectric focusing of the VLDL was performed accor-
ding to a procedure, slightly modified from that described by 
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- E - 3 
- E - 2 
- E - 1 
Figure 1. Isoelectric focusing gels of urea soluble apoproteins 
of VLDL. Left gel: type III subject with phenotype 
apoE-D (the apoE-3 band is lacking, apoE-2 is relative-
ly increased). Middle gel: control subject with pheno-
type apoE-N {apoE-4 band present, as in 28% of control 
subjects). Right gel: control subject with phenotype 
apoE-N {apoE-4 band absent). 
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Weidman et al (12). The lipoproteins were washed by a subsequent 
ultracentrifugation and delipidated in aceton: ethanol (1:1 v/v) 
according to Warnick et al (11). The delipidated apoproteins 
were dissolved in 0.2 M tns-HCl buffer in 8 M ureum, pH 8.2, 
containing 0.1% (w/v) dithiotreitol. The amount of protein 
measured with the Lowry method (25) loaded on the gel was 100 
to 400 pg. After isoelectric focusing the apoproteins were 
stained followed by densitometric scanning on a Shimadzu CS 910 
scanner within 3 days. The mterassay precision was determined 
using VLDL isolated from pooled serum. VLDL were divided in 
small aliquots and extracted separately; apoproteins were stored 
at -20 С prior to analysis. The mterassay coefficient of varia­
tion over a half year time period for the determination of the 
ratio apoE-3/E-2 was 9% (n=22). An example of VLDL apolipopro-
tein gels of subjects with phenotype apoE-N and Ε-D is given m 
figure 1. 
The relative body-weight is calculated as the ratio between 
the actual weight χ 100% and the ideal weight, based on Metro­
politan Life Insurance Tables (1959). All data are given as 
mean+1 standard deviation. For statistical analysis of diffe­
rences Student's t-test for unpaired observations was used. 
RESULTS 
Occurrence of hyper 1з poprotememia 
In 20 kindreds 93 first-degree and 15 2nd and 3rd-degree 
relatives have been studied. Their relation to the proband, 
mean age and the occurrence of hyperlipidemia are mentioned in 
table 1. In 44% of all relatives hyperlipidemia was established. 
Most of them were unaware of having abnormal serum lipids. Only 
in 3 kindreds, with only 1 or 2 relatives studied, no other 
case of hyperlipidemia was detected. There were more affected 
men than women among the relatives. Figure 2 shows that the 
occurrence of HLP increases with age. The occurrence was indeed 
higher among the parents and siblings than among the children of 
the probands (table 1). 
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number 
12 
10 
8 
6 
4 
2 
О 
О 20 40 60 80 
age(years) 
Figure 2. Occurrence of normolipidemia (NLP) and hyperlipidemia 
(HLP), according to age, in 93 first-degree relatives 
of 20 patients with type III hyperlipoproteinemia. 
Eight new cases of type III HLP were found in 8 pedigrees. 
Seven of them were siblings; one, a cousin, was known to have 
unclassified HLP with a history of myocardial infarction on the 
age of 46. More biochemical details of these subjects will be 
given in the next section. 
Seventy-three percent of all relatives with HLP had type 
IV HLP. All hyperlipidemic parents and children were classified 
as type IV. There were 5 cases of type Ila or type lib HLP (4 
siblings, 1 third-degree relative) occurring in 3 kindreds. 
Mean serum lipids and HDL-cholesterol in the normolipidemic 
and hyperlipidemic subjects are summarized in table 2. Among the 
subjects with type III HLP there were some with normal serum 
cholesterol, but all had hypertriglyceridemia. Among the type IV 
HLP subjects there were some with elevated serum cholesterol, 
but with normal LDL-cholesterol. The relatives with type III and 
type IV HLP had a significantly lower mean level of HDL-choles­
terol than those with normal serum lipids. 
Thirty five percent (17 out of 48) of the hyperlipidemic 
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Table 1. The occurrence of hyperlipoproteinemia in 108 relatives of 20 type III patients 
all subjects 
mean age 
(range) number 
parents 71(65-80) 6 
siblings 51(27-78) 58 
children 29(12-56) 29 
93 
2nd and 3rd-degree 30(16-78) 15 
108 
male/female 54/54 
subjects with hyperlipoproteinemia 
number (%) type IIa IIb III IV 
5 (83) - 5 
31 (53) 2 2 7 20 
8 (28) - 8 
44 (47) 2 2 7 33 
4 (27) 1 1 2 
48 (44) 3 2 8 35 
29/19 0/3 1/1 7/1 21/14 
LO 
Table 2. Serum lipids in 108 relatives of 20 patients with type III hyperlipoproteinemia (mean+SD (range) 
in mmol/l) 
η (m/f) mean serum cholesterol serum triglycerides 
age 
HDL-cholesterol 
normolipidemics 
hyperlipidemics 
type H a 
type lib 
type III 
type IV 
60(25/35) 
48(29/19) 
3(0/3) 
2(1/1) 
8(7/1) 
35(21/14) 
36 
53 
61 
55 
51 
52 
5.00+0.97(3.57-7.28) 1.09+0.3 3(0.45-1.72) 
8.60+0.65(7.87-9.14) 1.72+0.25(1.47-1.96) 
8.60 (8.00-9.19) 2.18 (2.09-2.26) 
8.47+3.28(4.83-14.45) 4.24+2.00(2.42-7.24) 
6.82+1.02(5.12-9.28) 3.48+1.37(1.85-7.68) 
1.49+0.28(1.01-2.31) 
1.38+0.36(1.16-1.79) 
1.23 (1.07-1.39) 
0.84+0.42*(0.43-1.24) 
1.16+0.31*(0.65-1.96) 
p<0.001 vs normolipidemics 
relatives had severe HLP (serum cholesterol above 9 and/or serum 
TG above 4 mmol/1): one case of type IIa, one case of type lib, 
4 cases of type III and 11 cases of type IV. As to age they were 
equally distributed over the whole range. 
Apoprotein E-phenotypes 
In sera of 80 subjects (78 first-degree and 2 other rela­
tives) out of 18 kindreds analytical isoelectric focusing of 
the VLDL-apoproteins was performed and the apoprotein E-3/E-2 
ratio was determined. Among these there were 6 parents and 20 
children, who could be considered as obligate heterozygous for 
apoE-3 deficiency according to the autosomal recessive mode of 
inheritance of deficiency of apoE-3 (9). The distribution of 
the apoE-3/E-2 ratio in these 26 subjects, together with 9 
obligate heterozygous relatives of a kindred with a combined 
deficiency of apoE-3, apoC-II and lipoprotein lipase, previous­
ly described by Stalenhoef et al (26), is shown in figure 3. 
number 1 
8 
6 
4 -
2 
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О 0.4 0.8 1.2 1.6 
apoE3/E2 ratio 
Figure 3. Distribution of the apoE-3/E-2 ratio in 26 first-
degree relatives of type III probands and 9 first-
degree relatives (shaded area) of probands with a 
combined deficiency of apoE-3, apoC-II and lipoprotein 
lipase described previously (26). According to the 
autosomal recessive mode of inheritance of apoE-3 
deficiency (9) these relatives could be considered 
as obligate heterozygous. 
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Thirty of these 35 subjects had a ratio between 0.4 and 1.2, 
considered to be the lower and upper limit of the ratio for the 
phenotype apoE-ND (12, 17). Five obligate heterozygous subjects 
had a ratio of 1.2, 1.3 or 1.4. Among the other relatives there 
were 4 subjects with a ratio between 1.1 and 1.5. As will be 
discussed below, they were considered to have phenotype apoE-N. 
A survey of the apoE-3/E-2 ratio in all studied relatives 
is shown in figure 4. The distribution seems to be trimodal with 
peaks at 0.1, 0.8 and 1.7, corresponding with the median of the 
three phenotypes. It is not possible to establish clear cut-off 
limits for the different phenotypes. So, some overlap must be 
present. 
^ n = 8 0 
η 
Ί I I I Γ ' ' Ί '>' 'I' ' 
0 0 5 1,0 15 2 0 2.5 >2.5 
apoE3/E2 ratio 
Figure 4. Distribution of the apoE-3/E-2 ratio in 80 relatives 
of 18 patients with type III hyperlipoproteinemia. 
In figure 5 two examples of the inheritance of apoE-3 
deficiency in a kindred is shown. The mode of inheritance in 
these and other pedigrees agrees with the observations of Uter-
mann et al (9). Pedigree В shows the vertical transmission of 
homozygous apoE-3 deficiency in the case of the mating of a 
type III HLP patient with a person with phenotype apoE-ND. There 
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Figure 5. Pedigrees of two families, showing the mode of inheri­
tance of apoE-3 deficiency. 
were insufficient informative matings in the other kindreds for 
segregation analysis. 
The relation between apoE-phenotype and occurrence of HLP 
in the family members is shown in table 3. More than half of the 
80 relatives had phenotype apoE-ND, most of the remaining were 
normal; only 13 had phenotype apoE-D. About half of the rela­
tives with each apoE-phenotype were hyperlipidemic, only slight­
ly more of those with phenotype apoE-D. Thirteen out of the 38 
patients with HLP had a severe form of HLP (serum cholesterol 
above 9, serum TG above 4 mmol/1): 3 out of 22 (14%) with pheno­
type apoE-N, 6 out of 4 5 (13%) with phenotype apoE-ND and 4 out 
of 13 (31%) with phenotype apoE-D. The mean age of subjects with 
phenotype apoE-ND was lower than that of the subjects with the 
other phenotypes but the difference was not significant (table 
3). The mean relative body-weight of the subjects with pheno­
type apoE-ND was significantly higher than that of the subjects 
with phenotype apoE-D, but not significantly different from 
that of the subjects with phenotype apoE-N. 
All hyperlipidemic subjects with phenotype apoE-ND had 
type IV HLP. Among hyperlipidemic subjects with phenotype apoE-N 
there were cases of type IIa, IIb and IV. All hyperlipidemic 
subjects with phenotype apoE-D had type III HLP by definition, 
but also when judged by the lipid composition of the VLDL. The 
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Table 3. The occurrence of hyperlipoproteinemia (HLP), according to the apoprotein E 
phenotype in 80 relatives of 18 type III patients 
all subjects 
apoprotein E phenotype 
apoE-N 
apoE-ND 
apoE-D 
mean 
age 
50 + 14 
4 3 + 18 
48 + 12 
mean relative 
body-weight 
116+18 
124+22 
110+17* 
number (m/f) 
22(13/9) 
45 (21/24) 
13(9/4) 
subjects 
number 
io11 
20 § 
8 + 
with HLP 
(%) 
(45) 
(44) 
(62) 
*p<0.05 vs apoE-ND 
2 type IIa, 2 type lib, 6 type IV 
20 type IV 
8 type III 
excess of cholesterol supported the diagnosis. The mean ratios 
between VLDL-cholesterol and serum TG and between VLDL-choles-
terol and VLDL-TG of all relatives with type III HLP is men-
tioned in table 4. The range of the first ratio was from 0.67 
to 1.44 and of the second ratio from 0.86 to 1.86. In six out 
of the 8 cases both ratios were above the value, that definitely 
establishes type III HLP (19, 20). In the other two cases with 
moderate HLP the value of the first ratio was suggestive for 
type III HLP (19) and the value of the second ratio was in one 
case ]ust below and in the other above the diagnostic limit 
(20). Mean HDL-cholesterol was significantly lower in the rela-
tives with type III HLP compared with that of the normolipid-
emics (table 4). 
The levels of serum lipids among the hyperlipidemic sub-
jects with the various phenotypes (table 4) is influenced by 
the occurrence of the different forms of HLP. Mean serum choles-
terol was high in hyperlipidemic subjects with phenotype apoE-N, 
because all type II HLP subjects were among them. Mean serum TG 
were high in hyperlipidemic subjects with phenotype apoE-ND; all 
of these having type IV HLP. There was no difference in mean 
HDL-cholesterol between the hyperlipidemic subjects with pheno-
type apoE-N and apoE-ND, but in both groups it was significantly 
decreased in comparison with the normolipidemic subjects. All 
hyperlipidemic subjects with phenotype apoE-ND and apoE-N had a 
normal lipid composition of the VLDL, as appears from the nor-
mal ratios between VLDL-cholesterol and serum- or VLDL-TG 
(table 4) . 
There appeared to be a striking difference between normo-
lipidemic relatives with phenotype apoE-D and those with apoE-N. 
Mean LDL-cholesterol was significantly lower in the apoE-D sub-
jects (table 4). Moreover, the mean ratios between VLDL-choles-
terol and serum- or VLDL-TG were significantly increased in the 
relatives with phenotype apoE-D, compared to those with pheno-
type apoE-N and E-ND (table 4). The range of the ratio between 
VLDL-cholesterol and serum TG in normolipidemic subjects with 
phenotype apoE-D was from 0.50 to 0.77, and of the ratio be-
tween VLDL-cholesterol and VLDL-TG from 0.7 4 to 1.28. In most 
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о Table 4. Serum lipids and lipoprotein fractions in 80 relatives of 18 type III patients, according to the 
apoprotein E phenotype (mean+SD in mmol/1) 
apoE η serum chol serum TG HDL-chol LDL-chol VLDL-chol VLDL-chol 
phenotype serum TG VLDL-TG 
hyperlipidemics apoË-N 10 7.21+1.31 2.82+0.94 1.15+0.30* 4.69+1.47 0.48+0.11 0.69+0.10 
apoE-ND 20 6.86+1.11 3.39+1.39 1.17+0.30* 3.97+0.71 0.48+0.11 0.66+0.13 
apoE-D 8 8.4 7+3.28 4.24+2.00 0.84+0.42* 3.58+0.92 0.94+0.27 1.23+0.35 
normolipidemics apoE-N 12 5.42+1.06 1.07+0.31 1.44+0.33 3.36+1.00 0.39+Ο.ΟΘ 0.66+0.24 
apoE-ND 25 4.99+1.00 1.10+0.35 1.48+0.27 3.01+0.92 0.40+0.09 0.78+0.20 
§ IT § 
apoE-D 5 4.49+1.17 1.34+0.36 1.47+0.13 2.20+0.87 0.60+0.11 0.97+0.21 
chol: cholesterol, TG: triglycerides 
»Ï 
H 
*p<0.05 vs normolipidemics with apoE-N 
p<0.001 vs apoE-N and apoE-ND 
p<0.05 vs apoE-N 
cases, however, the ratios were below the diagnostic limits for 
type III HLP. The ratios in norraolipidemic subjects with pheno-
type apoE-ND did not differ from those in subjects with pheno-
type apoE-N. 
In addition to a genetic predisposition for HLP, acquired 
factors such as an excessive intake of calories or ethanol and 
an impaired glucose tolerance might contribute to the develop-
ment of HLP in subjects with phenotype apoE-D. Therefore, con-
cerning some of these factors a comparison was made between 
apoE-3 deficient subjects with and without HLP. No significant 
difference emerged in mean relative body-weight between the two 
groups (resp. 115+9 and 101+25%). In both the hyperlipidemic and 
the normolipidemic group there were two obese subjects with a 
relative body-weight over 120%. All subjects with phenotype 
apoE-D whether or not with HLP had family members with HLP, 
other than the proband. Seven of the 8 subjects with HLP were 
men, one a postmenopausal woman. Among the normolipidemic sub-
jects there were two men and three women, two premenopausal (the 
two obese normolipidemic subjects) and one postmenopausal. There 
are no data about the glucose tolerance of these subjects. There 
was no admitted excessive intake of ethanol. 
DISCUSSION 
All family studies in type III HLP revealed a high occur-
rence of hyperlipidemia among relatives (2-7). Our study is in 
agreement with these reports and establishes also in the Nether-
lands a frequency of hyperlipidemia of about 50% among first-
degree relatives of type III patients. In almost all kindreds 
there were cases of HLP. Most subjects were unaware of having 
elevated blood lipids. Most cases were classified as type IV 
HLP, only a minority as type III or type II. In most of the 
previous studies there were as many type III as type IV cases. 
This difference has to be ascribed to the more specific cri-
teria for the diagnosis type III HLP used in our study, which 
included the lack of apoprotein E-3. In the other studies the 
diagnosis type III HLP was only based on the electrophoretic 
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pattern of the VLDL whether or not in combination with the cho-
lesterol content of VLDL. We now know that VLDL with ß-mobility 
also may occur in subjects with phenotypes other than apoE-D (5, 
12) . 
In most pedigrees there were cases of type III and type IV 
HLP, m a few type II, III and IV HLP. New cases of type III HLP 
among first-degree relatives were only found in siblings and not 
m children of the probands. The high incidence of HLP among 
relatives stresses the importance of screening these subjects 
for HLP. Our results (fig. 2) suggest that it is only worth-
while to screen relatives above the age of about 30 years, be-
cause the expression of type III and IV mainly occurs in adult 
age. This is m contrast with family studies in familial hyper-
cholesterolemia, a disorder becoming manifest already in child-
hood ( 1 ) . 
For the separation of the three apoE-phenotypes we used as 
cut-off points for the ratio apoE-3/E-2 the values 0.40 and 1.15 
as m other studies, applying the same procedure of isoelectric 
focusing (12, 13). Thirty of the 35 obligate heterozygous sub-
jects had values within these limits. Five subjects had a ratio 
of 1.2, 1.3 or 1.4, indicating a normal apoE-phenotype. Our 
study shows that there are no sharp cut-off limits for the dif-
ferent apoE-phenotypes, at least when only one analysis is done. 
We also found a trimodal distribution with unsharp cut-off 
limits of the apoE-3/E-2 ratio in about 400 sera of normolipid-
emic controls, various hyperlipoprotememic patients and their 
relatives (unpublished observations, Ρ Stuyt, A Stalenhoef, 
Ρ Demacker, A van 't Laar). Therefore, a single determination 
resulting in an apoE-3/E-2 ratio of about C.3 around the cut-off 
limits is not conclusive for an apoprotein E-phenotype and a 
second analysis is needed. Unfortunately it was neither possible 
to restudy these 35 obligate heterozygous relatives, nor 4 other 
relatives with such an unconclusive ratio. To be in concordance 
with the above mentioned studies and to obtain a pure group of 
subjects with phenotype apoE-ND because of the aim of the study, 
the latter 4 subjects were considered to have phenotype apoE-N. 
The inheritance of apoprotein E-3 deficiency in the 18 
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kindreds in this study was m agreement with the autosomal re-
cessive mode as originally described by Utermann et al (5, 9) . 
All first-degree relatives with phenotype apoE-D were siblings 
of a type III HLP patient, except one child of a mating of a 
type III HLP patient and a subject with phenotype apoE-ND. This 
illustrates that vertical transmission of phenotype apoE-D and 
the more so of type III HLP, is rather exceptional, but possible 
by the relative high occurrence of phenotype apoE-ND in the 
population. 
The expression of HLP m subjects with phenotype apoE-D is 
said to be influenced by genetic and environmental factors, 
such as familial predisposition for HLP (5, 9) and intake of 
calories and ethanol (16). In the families of all 13 relatives 
with phenotype apoE-D other cases of HLP were found; a familial 
predisposition to HLP might be considered in all. However, 5 of 
these 13 were normolipidemic. In three of them this could pos-
sibly be explained by their low body-weight. The other two were 
premenopausal obese women and presumably protected against the 
development of HLP as a result of the paradoxically hypolipid-
emic effect of estrogen (27). The follow-up of these women would 
be interesting because they are at great risk to develop HLP 
after the menopause as a consequence of their overweight. These 
results are in agreement with the hypothesis that there are 
additional factors necessary to induce HLP in subjects with 
phenotype apoE-D. Because it appears to be always type III HLP, 
which arises in those cases, carrying a great risk of vascular 
disease, it seems important to screen relatives of type III HLP 
patients for phenotype apoE-D. In subjects with the other pheno-
types, these factors induce mostly type IV, which has less con-
sequences . 
The lipid composition of the lipoproteins of the relatives 
with phenotype apoE-D and HLP fulfilled the criteria for type 
III HLP, namely a high cholesterol content of the VLDL (5, 19, 
20). Because of the removal defect of the VLDL-remnants a low 
LDL-cholesterol level would be expected. However, these sub-
jects appeared to have a normal level (table 4). This could be 
explained by the presence of a part of the accumulated remnant 
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particles in the LDL-fraction. In the 5 normolipidemic subjects 
with phenotype apoE-D, LDL-cholesterol was low. The ratio be-
tween VLDL-cholesterol and serum- or VLDL-TG was significantly 
higher than in the subjects with phenotype apoE-N, but in most 
of them these values did not fulfil the criteria for type III 
HLP. These data are in agreement with previous studies (5, 18). 
The rather high level of cholesterol in VLDL and the low LDL-
cholesterol value in these subjects indicates an increase of 
VLDL-remnants as a consequence of the defect in the conversion 
of remnants to LDL, as was postulated by Utermann et al (5, 18). 
HDL-cholesterol was normal in the normolipidemic subjects with 
phenotype apoE-D, m contrast with the low value in the hyper-
lipidemic subjects with this phenotype. It suggests that the 
decrease in HDL-cholesterol is related to the HLP and not to be 
the lack of apoprotein E-3. 
The removal defect of VLDL-remnants in type III HLP sub-
jects may be associated with the deficiency of apoprotein E-3 
(14). It is therefore conceivable that also in the heterozygous 
deficient state (phenotype apoE-ND) disturbances in lipoprotein 
metabolism could be present. Indeed there are reports of a 
higher prevalence of hyperlipidemia among these subjects (5, 17), 
the presence of ß-VLDL (5) and a higher cholesterol content of 
VLDL (5, 13, 18). These findings could not be confirmed by us 
and by others (12). The occurrence of HLP was not greater among 
subjects with phenotype apoE-ND than among those with phenotype 
apoE-N. The younger age of our subjects with phenotype apoE-ND 
could be related to this finding, but on the other hand, their 
body-weight was higher than that of the subjects with phenotype 
apoE-N (table 3). The cholesterol content of the VLDL was the 
same in both groups. This would be reassuring because the fre-
quency of phenotype apoE-ND in the population is 15% and remnant 
particles are, together with the cholesterol-rich LDL, the most 
atherogenic lipoproteins (28). ApoE-D subjects, however, having 
an increase in VLDL-remnants, even without HLP, might have a 
greater risk of vascular disease. This would strengthen the case 
for the screening of relatives for apoE-3 deficiency. Further 
studies are needed in order to investigate the incidence of 
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atherosclerotic complications among subjects with phenotype 
apoE-D and apoE-ND. 
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CHAPTER 4 
LONG-TERM TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA 
WITH CLOFIBRATE 
PMJ Stuyt, PNM Demacker, A van 't Laar 
Atherosclerosis 1981; 40: 329-336 
ABSTRACT 
In this retrospective study we report the results of treat-
ment with Clofibrate during at least 7 years in 9 patients with 
severe type III hyperlipoproteinemia. 
Initial treatment consisted of a diet, restricted in fat and 
calories. Because of insufficient response additional therapy 
with 2 grams Clofibrate daily was given. Serum cholesterol de-
creased significantly from 14.3+4.4 mmol/1 (mean + SD), on diet 
therapy, to average annual values ranging from 9.0+4.9 to 7.9+2.0 
and serum triglycerides decreased significantly from 5.6+1.9 to 
average annual values from 3.8+1.8 to 2.0+0.7, despite a slight 
gam in body-weight. Serious side-effects did not occur. 
After several years of treatment with Clofibrate the drug 
was withdrawn temporarily. Serum lipids increased significantly 
in all patients to a level, not different from that before the 
start of drug therapy. 
It is concluded that Clofibrate is a strong hypolipidemic 
drug for the treatment of type III hyperlipoproteinemia and that 
it does not lose efficacy even after 7 years of use. 
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INTRODUCTION 
Type III hyperlipoproteinemia (HLP) is a familial distur-
bance in lipoprotein metabolism, complicated by the occurrence 
of xanthomas and a strong predisposition for cardiovascular 
disease (1). Serum cholesterol and serum triglycerides (TG) are 
both elevated. The very low density lipoproteins (VLDL) are 
relatively rich in cholesterol and have a reduced electro-
phoretic mobility (ß-VLDL). There is an accumulation of VLDL-
remnants (2, 3). In the VLDL-fraction one of the apoE isopro-
teins, apoE-3, is lacking (4). 
In contrast to some other kinds of HLP, type III is emi-
nently treatable (1, 5). A calorie- and fat-restricted diet is 
indicated, which may be combined with Clofibrate when the lipid 
lowering effect of diet alone is insufficient. The short-term 
effect of diet, whether or not with Clofibrate has been well 
documented (1, 5-9). However, there are no data about the long-
term effect of these therapeutical measures. In this retrospec-
tive study we report the results of long-term treatment with 
Clofibrate of patients with type III HLP. 
MATERIALS AND METHODS 
This study concerns those type III patients from our out-
patients department, who have been treated with Clofibrate for 
at least 7 years (mean 8.2, range 7-9). One of the ten patients 
was excluded because there were insufficient follow-up data, 
leaving 6 male and 3 female patients. Table 1 comprises the 
clinical and biochemical features at the time of diagnosis and 
just before the start of Clofibrate. Seven patients had xantho-
mas (5 palmar, 7 tuberous, 1 tendinous xanthomas). Four patients 
had coronary heart disease, two of them also peripheral vascular 
disease. A diagnosis of coronary heart disease was made if the 
patient had either a classic history of angina pectoris or 
obvious electrocardiographic evidence of myocardial infarction. 
Peripheral vascular disease was considered to be present if the 
patient had intermittent claudication with decreased or absent 
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Table 1. Clinical and biochemical features of 9 patients with type III hyperlipoproteinemia 
Patient Sex 
1 m 
2 f 
3 f 
4 m 
5 m 
6 m 
7 m 
8 m 
9 f 
at time of diagnosis 
age body relative* serum serum 
(yrs) weight weight Chol TG 
kg г mmol/1 mmol/l 
49 66.5 104 13.6 
54 94.6 174 14.7 6.4 
49 73.3 126 25.4 
43 79.8 127 23.0 
53 72.1 116 11.5 5.3 
39 81.5 125 12.5 
32 82.0 119 12.3 
41 97.6 137 23.0 
45 61.8 125 17.2 
last value before Clofibrate 
body relative serum serum 
weight weight Chol TG 
kg Ί mmol/l mmol/l 
65.9 103 13.9 5.4 
80.8 149 11.0 5.0 
67.7 117 15.1 9.8 
82.2 131 19.8 
69.0 111 11.5 3.9 
79.1 121 9.6 5.6 
75.4 109 13.1 4.7 
81.6 115 18.5 
62.7 127 18.6 4.2 
clinical symptoms at 
time of diagnosis 
CVD 
xanthomatosis 
xanthomatosis, CVD 
xanthomatosis 
CVD 
xanthomatosis 
xanthomatosis 
xanthomatosis 
xanthomatosis, CVD 
Choi: cholesterol; TG triglycerides 
CVD: cardiovascular disease 
*Actual weight χ lOOo, divided by ideal weight, based on Metropolitan Life Insurance Tables (1959) 
peripheral pulses. The diagnosis type III HLP was originally 
based on the clinical picture and the characteristic broad β 
band on cellulose acetate electrophoresis. Later the diagnosis 
had been confirmed using other diagnostic criteria. The VLDL-
fraction proved to be relatively cholesterol-rich, resulting 
in a ratio between VLDL-cholesterol and serum-TG of more than 
0.69 (10) and a ratio between VLDL-cholesterol and VLDL-TG of 
more than 0.92 (11). The VLDL of all patients had β mobility 
with electrophoresis on agarose (group 5 pattern according to 
Demacker et al (12)) and were deficient of apoprotein E-3 (4). 
In 6 patients a familial form of type III HLP had been demon­
strated. Secondary forms of HLP were excluded. None of the 
patients had clinical diabetes mellitus. 
All patients were initially treated with a hypocaloric 
diet with a moderate fat reduction (30 to 35% of total calories). 
Most patients lost body-weight and serum lipids decreased but 
remained above normal (table 1). Therefore, Clofibrate in a dose 
of 1 gram twice a day was prescribed. The period of treatment 
with diet varied from six months to several years. At the start 
of treatment with Clofibrate the diet remained unchanged. The 
values of serum lipids and body-weight given for each examina­
tion period are the averages of at least 2 (mean: 4) determina­
tions in each patient. In all patients Clofibrate has been 
withdrawn temporarily after 3 to 8 years (mean: 6) of therapy 
to test the enduring hypolipidemic effect of Clofibrate. The 
diet remained unchanged. The mean values of the last year before 
the withdrawal were compared with the mean values during the 3 
to 8 months without therapy. 
Blood samples were taken by venepuncture after an overnight 
fast. Cholesterol was initially determined with the FeCl,-H
o
S0. 
1
 3 2 4 
method (13). Later, at different times in the course of treat­
ment of each patient, the automated method with use of Lieber-
mann-Burchard reagent (14) was introduced. The results obtained 
for 200 sera with both methods showed good agreement. Triglyce­
rides were initially determined with an enzymatic method (15), 
using commercially available reagent (Boehnnger, Mannheim, FRG). 
Later a semi-automated colorimetrie method was used (16). Again 
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both methods agreed well (16). 
Lipoprotein electrophoresis on cellulose-acetate was done 
according to Chin and Blankenhorn (17). The lipoprotein bands 
were coloured according to Kohn (18). The methods for separation 
and determination of the lipoprotein fractions with ultracentri-
fugation and by agarose gel electrophoresis were described pre-
viously (12, 19). The ratio apoprotein E-3/E-2 in the VLDL was 
determined with analytical isoelectric focusing (20). 
All values are given as mean + 1 standard deviation. 
Student's t-test for paired observations was used to test dif-
ferences for significance. 
RESULTS 
Effect of Clofibrate 
In all patients there was a strong fall in serum lipids in 
the first year of treatment with Clofibrate (table 2). In 2 
patients no serum-TG values were known at the start of the 
Clofibrate therapy. In the first year of Clofibrate there was 
a significant mean body-weight gain of almost 2 kg. In table 2 
also the basal values of the serum lipids and body-weight are 
mentioned. The mean basal serum-TG level is not given, because 
it has not been determined in most of the patients. In the long 
run the hypolipidemic effect of Clofibrate persisted (figure 1). 
During 7 years the mean annual values of cholesterol ranged 
from 7.9+2.0 to 9.0+4.9 mmol/l (for every year p<0.001 vs diet); 
the mean annual serum-TG levels (in 7 patients) ranged from 
2.0+0.7 to 3.8+1.8 mmol/l (for every year p<0.01 vs diet). The 
mean annual values of body-weight ranged between 75.7+7.6 kg 
and 76.8+9.7 kg. The slight weight-gain in the first year of 
Clofibrate treatment persisted. Five of the nine patients have 
been treated with Clofibrate for nine years. Serum lipids and 
body-weight remained at the same level in all. 
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Table 2. Effect of clofxbrate m 9 patients with type III hyperlipoproteinemia 
basal diet Clofibrate Clofibrate diet (after 
(first year) (year before withdrawal) 
withdrawal) 
Serum cholesterol (n=9) 17.0+5.4 14.3+4.4* 
(mmol/1) 
Serum triglycerides (n=7) - 5.6+1.9 
(mmol/1) (n=9) 
Body-weight (n=9) 78.6+11.7 73.8+7.1* 75.7+7.6*'°° 76.8+8.9* 75.8+8.8* 
Mean + SD 
Basal value is the mean value before treatment 
Diet value is the mean value in the last 6-12 months before start of Clofibrate 
Clofibrate (first year) value is the mean value m the first year of treatment with Clofibrate 
Clofibrate (year before withdrawal) value is the mean value in the last year before with-
drawal of Clofibrate 
Diet (after withdrawal) value is the mean value in the 3 to 8 months after withdrawal of 
Clofibrate 
*p<0.05 vs basal value 
p<0.001 vs basal value and diet value 
§ 
p<0.01 vs diet value 
p<0.005 vs value with Clofibrate (year before withdrawal) 
p<0.05 vs value with Clofibrate (year before withdrawal) 
p<0.05 vs diet value 
8.5+3.2 7.5+1.9 12.7+5.6 
2.9+0.8· 3.0+0.9 
3.8+1.9 
§ 4.7+1.91 
7.6+6.9^ 
kg 
90-
80-
70-
mmol/l 
16-
12 -
CLOFIBRATE 
mean ι SD 
weight(n= 9) 
T cholesterol (n= 9) 
ι—ι—ι—ι—ι—ι—ι—ι­
ο ί 2 3 4 5 6 7 
Time (years) 
Figure 1. Serum lipids and body-weight in 9 patients with type 
III hyperlipoproteinemia during treatment with Clofi­
brate. The values in the period of temporary with­
drawal of Clofibrate were excluded. All values during 
treatment with Clofibrate were significantly different 
from the initial value (cholesterol p<0.001, trigly­
cerides p<0.01; body-weight p<0.05). 
Effect of withdrawal of Clofibrate 
After 3 to 8 years (mean 6) of treatment with Clofibrate 
the drug was withdrawn. Serum cholesterol increased m all 
patients and serum TG in 8 of the 9 patients. Mean serum choles­
terol rose significantly to a level, not significantly different 
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from that before the start of drug therapy (table 2). The in-
crease of mean serum TG was also significant. Mean serum TG in 
the 7 patients with known pretreatment values rose after with-
drawal to a level, also not significantly different from that 
before Clofibrate (table 2). The mean body-weight did not change 
significantly. 
Changes in clinical parameters 
In 5 of the 7 patients (no. 2, 3, 6, 7, 9) there was a 
complete disappearance and in 2 patients (no. 4 and 8) there 
was an evident but incomplete regression of the xanthomas. 
In 2 patients (no. 3 and 5) with known coronary heart 
disease there was no progression: no or stable angina pectoris 
and no myocardial remf arction. One patient (no. 1) with both 
coronary (myocardial infarction 10 years before start of Clofi-
brate) and peripheral vascular disease, without progression 
during treatment, died acutely at home m the 8th year of 
treatment with Clofibrate. There was no autopsy. Three patients 
with the highest and still elevated serum lipids during therapy 
had progressive atherosclerotic disease: two patients (no. 4 
and 7) without complaints of cardiovascular disease before 
treatment underwent bypass surgery: one (no. 4) a coronary by-
pass because of severe angina pectoris in the 7th year of 
treatment, the other (no. 7) a peripheral bypass for arterial 
obstruction in the 7th year of Clofibrate treatment. Patient 
no. 9 with known coronary and peripheral vascular disease, got 
a peripheral bypass in the 5th year and a coronary bypass in 
the 9th year of treatment because of progressive symptoms. Three 
patients (no. 2, 6, 7) had no signs of cardiovascular disease 
before and during therapy. 
Side-effects 
None of the patients mentioned serious side-effects. Regu-
larly taken blood samples for renal and hepatic function and 
creatinine Phosphokinase activity did not show abnormalities, 
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except for a decrease in the alkaline phosphatase activity as 
we described earlier in type II and IV patients (21). In 4 of 8 
patients cholelithiasis has been demonstrated. In two of these 
cholecystectomy had been performed already before the start of 
Clofibrate; in the other two patients "silent" gallstones were 
demonstrated during treatment, but there was no previous exam-
ination. One subject has not been examined for the presence of 
gallstones. 
DISCUSSION 
Type III HLP is characterized clinically by the occurrence 
of disfiguring xanthomas and a strong predisposition for cardio-
vascular disease (1). The response of serum lipids on therapy 
with diet and Clofibrate is impressive (1, 5-9). However, these 
studies have been done over time-periods of a few weeks or 
months, and it has never been demonstrated whether these results 
can be maintained during a long period of treatment. 
In this retrospective study the results of treatment with 
Clofibrate during at least 7 years in 9 type III patients are 
shown. Clofibrate, which was added to diet therapy, decreased 
serum lipids with 40 to 50 percent in the first year. This is 
in agreement with previous reports (5, 7, 9). The hypolipidemic 
effect of Clofibrate remained unchanged during the seven years 
of follow-up, despite a slight gain in body-weight. Temporary 
withdrawal of Clofibrate after several years resulted in an in-
crease of serum lipids to about the same level as in the pre-
treatment period. 
The decrease of serum cholesterol during dietary treatment 
(16%) in this study is small in comparison with previous studies 
(40-50%) (5, 7, 9). However, those papers reported on short-term 
observations. In our patients treatment with diet alone lasted 
several months to several years. So, at the end of this period 
compliance could be less and the body-weight was not declining 
anymore. 
There are some reports of subjective relief of cardiovascu-
lar disease during short-term therapy (5, 7, 9). One study men-
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tioned an increase in peak reactive hyperemia blood flow in the 
legs after short-term therapy (22). Long-term observation in our 
patients showed different patterns. Of course, conclusions about 
a bemficial effect of lipid reduction on cardiovascular disease 
can not be drawn from these observations in a small number of 
patients. As in other studies (5, 9), xanthomas disappeared 
mostly or diminished. 
Serious side-effects of Clofibrate did not occur. There 
was a high prevalence of gallstones in our patients. Although 
it is known that during Clofibrate the risk for gallstones in-
creases (23, 24), it cannot be concluded that the drug is 
entirely responsible in our patients. Some patients had chole-
lithiasis already before the start of treatment and others had 
not been subjected to a previous X-ray examination. 
The outcome of the WHO-trial (24), the excess in mortality 
in the clofibrate-treated group, has made the drug controversial. 
Indeed, there seems to be no place for Clofibrate as a drug for 
a community-wide primary prevention of coronary heart disease. 
However, Clofibrate is a useful agent in selected patients. In 
this study we have shown that it is a strong hypolipidemic drug 
for the long-term treatment of type III HLP. Further studies are 
needed for the assessment of the effect on cardiovascular dis-
ease in this type of patients. 
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CHAPTER 5 
EFFECT OF INFUSION OF NORMAL PLASMA ON LIPOPROTEINS IN 
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ABSTRACT 
The removal defect of remnants of very low density lipo-
proteins (VLDL) m type III hyperlipoproteineinia may be related 
to the deficiency of apolipoprotein E-3. Therefore, 2 units 
donor plasma with a normal apoE-3 content were administered to 
a patient with this disorder. Follow-up during 15 days showed 
no change in the serum lipids and lipoprotein fractions. On the 
apoprotein gels of VLDL no clear apoE-3 band became visible. 
Several explanations for this negative result are discussed. 
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INTRODUCTION 
In normal subjects most very low density lipoproteins 
fVLDL) are catabolized to low density lipoproteins (LDL) via 
short-living intermediates, VLDL-remnants. In type III hyper-
lipoproteinemia (HLP) (broad-ß-disease) there is an accumulation 
of VLDL-remnants, probably caused by a defect in the removal of 
these remnants, whether or not combined with overproduction of 
VLDL. The VLDL-fraction is missing one of the apolipoprotein E 
subspecies (apoE-3) resulting m a low apoE-3/E-2 ratio (1). 
Massive hypertriglyceridemia has been described, caused by 
a deficiency of apolipoprotein C-II. This apolipoprotein is the 
activating factor of lipoprotein lipase (LPL), the enzyme regu-
lating the catabolism of triglyceride (TG)-rich particles. 
Infusion of normal plasma supplying the missing activating 
factor for LPL, resulted in a dramatic fall in plasma TG (2). 
ApoE-3 deficiency may be the basal defect in the catabolism 
of VLDL-remnants, since apoE is important m lipoprotein remnant 
uptake by the liver through the interaction with an apoE recep-
tor on the hepatocyte membrane (3). Attempts to correct this 
defect by infusion of normal plasma have not yet been reported. 
We investigated whether infusion of plasma in a type III patient 
would provide sufficient apoE-3 to correct the removal-defect on 
the analogy of the effect of infusion of plasma in apoC-II defi-
ciency. 
METHODS AND RESULTS 
Two units of plasma (each 250 ml) were obtained from two 
healthy donors with a normal apoE composition (table) and ad-
ministered in 45 minutes to a 31 year old patient with all the 
features of type III HLP (table). During the observation on an 
outpatient base the moderately fat-restricted diet remained 
unchanged. The body-weight did not change more than 2%. 
Methods for determination of lipoproteins and VLDL-apo-
lipoprotems (by isoelectric focusing) were described previously 
(4) . 
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Table. Lipids and apoproteins of donors and recipient 
serum 
Chol TG 
VLDL 
Chol TG 
VLDL-chol* E-3 
apo 
VLDL-TG E-2 
donor 1" 
E 
donor 2" 
4.30 0.97 0.45 0.73 0.62 
7.37 2.34 1.10 1.62 0.68 
2.55 
2.33 
recipient 
day -3 
0 before plasma 
15' after plasma 
300' after plasma 
1 
2 
3 
4 
7 
10 
17 
24 
7.90 3.74 4.17 
8.01 5.84 5.06 
6.95 4.88 4.13 
8.01 5.72 4.86 
9.29 10.52 6.04 
9.32 8.00 5.49 
8.91 4.68 4.91 
8.21 3.82 4.26 
7.79 9.72 4.77 
6.98 4.62 4.68 
8.20 5.48 4.94 
9.29 6.24 6.67 
2 .92 
4 . 8 4 
4 . 2 2 
5 .16 
9 .14 
6 . 2 7 
3 .64 
2 . 9 9 
7 .56 
3 .66 
4 . 1 8 
5 .02 
1.43 
1.05 
0 . 9 8 
0 .94 
0 .66 
0 . 8 8 
1.35 
1.42 
0 .63 
1.28 
1.18 
1.33 
0 .12 
0 .00 
0 .07 
0 .08 
0 .00 
0 .00 
0 .08 
0 .15 
0 .00 
0 .00 
0 .28 
+ 
n . d . + 
chol: cholesterol (mmol/1) 
TG: triglycerides (mmol/1) 
*>0.92 is diagnostic for type III HLP 
>1.30- normal 
0.30-1.10: heterozygous E-3 deficiency (intermediate level) 
<0.30: homozygous E-3 deficiency 
non-fasting blood sample 
no apoE-3 peak visible 
§ 
not determined 
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Infusion of plasma did not result in a marked decrease of 
serum lipids during the observation period of 24 days (table). 
On some days even an increase of serum lipids was seen. However, 
variability in serum lipids is typical for type III HLP. The 
specific type III pattern, the cholesterol nchdom of the VLDL-
fraction, remained unchanged, although on some days the ratios 
VLDL-cholesterol/serum- or VLDL-TG fell below values, diagnostic 
for type III HLP. This can be explained by the much greater in-
crease of serum TG compared to serum cholesterol and not by a 
trend in the direction of normality. On the day of infusion and 
the following days no clear apoE-3 band was visible. The apoE-3/ 
E-2 ratio remained below 0.30, indicating apoE-3 deficiency. 
DISCUSSION 
In type III HLP the defect in removal of VLDL-remnants may 
be associated with the apoE-3 deficiency (3). Infusion of plas-
ma, obtained from donors with normal apoE-3 concentration, 
failed to normalize serum lipids and the specific type III 
pattern. 
It could be possible that two units of plasma contain an 
insufficient amount of apoE-3 to correct the removal defect. 
Indeed, in some subjects with an intermediate concentration of 
apoE-3 (ratio apoE-3/E-2: 0.30-1.10) the presence of ß-VLDL has 
been demonstrated, indicating an accumulation of VLDL-remnants 
(1). On the other hand, our results could mean that the apoE-3 
deficiency is not the only factor responsible for the removal 
defect. This would be m agreement with the observation by 
Falko et al (5), who found a complete normalisation of the 
serum lipids and of the VLDL-composition during treatment with 
estrogen despite the persistent apoE-3 deficiency. A third 
explanation could be that apoE-3 is not fully transferable 
between the lipoproteins of donor and recipient. 
On the VLDL-apoprotein gels no distinct apoE-3 band became 
visible after infusion of the plasma. This must be explained by 
several dilution factors. First, the administered plasma was 
diluted 5 fold in the recipients plasma. Secondly, in a type 
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Ill HLP patient total VLDL-apoprotein is about 10 times in­
creased per volume unit of plasma. Because only a limited 
amount of protein (<400 цд) can be loaded onto the gel, and 
because this amount is the same for normal and type III HLP 
VLDL-apoprotem, relatively less apoE-3 administered in the 
patient is applied for isoelectric focusing. Thus, the total 
dilution was about 50 fold. 
In conclusion, our results suggest that apoE-3 does not 
play a role as co-factor in the removal of remnants that is 
as critical as that of apoC-II in the catabolism of TG-nch 
particles. 
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CHAPTER 6 
THE TURNOVER OF VLDL-TRIGLYCERIDES IN TYPE III 
HYPERLIPOPROTEINEMIA 
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ABSTRACT 
To study the contribution of overproduction of very low 
density lipoprotein (VLDL) to the pathogenesis of type III 
hyperlipoproteinemia the turnover rates of plasma triglycerides 
and VLDL-triglycerides were measured in 7 type III patients and 
compared with the results m 15 normal subjects and 9 type IV 
patients. Use was made of the single injection H-glycerol 
method. Arguments are presented for the validity of this method 
in the study of type III subjects. 
The mean (+ SD) value for the turnover rate of plasma 
triglycerides in type III patients amounted to 19.8+8.4 pinol. 
kg .h (range 11.9-33.6). In the normal subjects and type IV 
patients these values were 10.2+3.1 (6.0-15.0) and 20.1+8.7 
(8.0-32.5). The mean turnover rate of VLDL-triglycerides m the 
type III patients was 18.1+4.8 ymol.kg-1.h-1 (13.7-26.1). These 
data suggest that overproduction of VLDL-triglycerides contrib-
utes to the pathogenesis of type III hyperlipoproteinemia. 
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INTRODUCTION 
In type III hyperlipoproteinemia (HLP), a familial distur­
bance in the metabolism of plasma lipoproteins, the very low 
density lipoproteins (VLDL) have an abnormally high cholesterol 
content and a reduced electrophoretic mobility (1). There is an 
accumulation of VLDL-remnants (Sf 20-100), which are intermedi­
ate products in the conversion of VLDL to low density lipopro­
teins (LDL) (2, 3). The pathogenesis has not been fully eluci­
dated. A disturbance in the catabolism of VLDL-remnants is like­
ly (4). However, there are also indications for an overproduc­
tion of VLDL (5). A third possibility is a direct synthesis of 
lipoproteins with abnormal composition. Indeed, VLDL seem to be 
deficient of one of the apoE isoproteins (apoE-3) (6), whereas 
the total amount of the apoprotein E is elevated (7). 
Using the Η-glycerol method, we studied whether overproduc­
tion of VLDL-TG contributes to the pathogenesis of type III HLP. 
MATERIALS AND METHODS 
Patients 
This study concerns 7 patients with type III HLP. Table 1 
comprises their clinical and biochemical features. The ratio 
between VLDL-cholesterol and serum TG and between VLDL-choles-
terol and VLDL-TG (expressed in mmol/1) were in all patients 
more than 0.69 and 0.92, respectively; both are considered as 
establishing type III HLP (8, 9). In all patients VLDL had ß-
mobility on agarose-electrophoresis, whereas on analytical 
isoelectric focusing the VLDL of all patients were lacking 
apoprotein E-3. In six patients a familial form of type III HLP 
was demonstrated. Secondary forms of HLP were excluded. None of 
the patients had clinical diabetes mellitus. As reference groups 
for the turnover studies we used 15 normal subjects (11 males 
and 4 females, mean age 46+12 years, mean relative body-weight 
117+19%) and 9 patients with type IV HLP (5 males, 4 females 
mean age 48+9 years, mean relative weight 123 + 12%) . The groups 
did not differ significantly in age and body-weight. The rela-
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^ Table 1. Clinical and biochemical features of the patients with type III hyperlipoproteinemia 
о 
Patient 1 2 3 4 5 6 7 
Sex 
Age (years) 
Weight (kg) 
Relative weight (%) 
Xanthomatosis 
Ischemic heart disease 
Peripheral vascular disease 
Serum cholesterol (chol) (mmol/l) 
Serum triglycerides (TG) (mmol/l) 
VLDL-chol (mmol/l) 
VLDL-TG (mmol/l) 
VLDL-chol/serum TG 
VLDL-chol/VLDL-TG 
B-VLDL 
Apoprotein E-3 deficiency* 
M 
47 
69 
no 
-
+ 
-
10.98 
4.55 
5.06 
3.86 
1.11 
1.31 
+ 
+ 
F 
53 
67 
135 
+ 
+ 
+ 
23.18 
8.42 
16.23 
6.91 
1.93 
2.35 
+ 
+ 
M 
57 
68 
107 
-
+ 
-
9.32 
5.38 
4.74 
5.03 
0.88 
0.94 
+ 
+ 
F 
66 
58 
116 
-
-
-
11 .18 
5.13 
6.00 
4.08 
1.17 
1.47 
+ 
+ 
F 
59 
76 
138 
+ 
-
+ 
15.03 
12.86 
11 .99 
12.07 
0.93 
0.99 
+ 
+ 
M 
31 
101 
162 
-
-
-
12.00 
7.98 
8.76 
6.30 
1.10 
1.39 
+ 
+ 
F 
58 
60 
127 
-
-
-
7.60 
4.52 
4.00 
3.16 
0.88 
1.27 
+ 
+ 
'Apoprotein E-3/E-2 ratio below 0.30 
tive body-weight was calculated as the ratio between the actual 
weight χ 100% and the ideal weight, based on Metropolitan Life 
Insurance Tables (1959). 
All subjects were studied as outpatients. For at least 
two months prior to the study no drugs were used, which could 
influence lipid metabolism. The patients used a moderately fat-
restricted diet. All subjects had given informed consent to the 
study. 
Measurement of the turnover of plasma- and VLDL-triglycendes 
As an estimation for the production of VLDL, the turnover 
rate of plasma- and VLDL-TG was measured during a steady state, 
according to the method originally described by Farquhar et al 
(10). After an overnight fast 50 pCi 2- Η-glycerol (the Radio­
chemical Centre, Amersham, England) was administered by an 
intravenous pulse injection. In vivo this label is partially 
incorporated in the VLDL-TG. Until 7 hours after the injection 
nine blood samples were obtained, while the patient continued 
to fast. The VLDL-f raction was isolated by ultracentnf ugation. 
Triglycerides were extracted according to Royer and Ko (11). 
The slope of the specific activity of the VLDL-TG against time 
curve was determined and the fractional catabolic rate (FCR) 
calculated. All curves had a mono-exponential decay. During the 
experiments there existed a steady state as to the plasma TG 
(less than 15% difference from the initial value). The absolute 
turnover rate was computed using the formula V = К χ С χ g, 
where V is the absolute turnover rate (pmol.kg .h ), К the 
fractional turnover rate (h ), С the concentration of VLDL-TG 
(mmol/1) and g the plasma volume per kg body-weight (ml/kg), 
calculated from the formule 
_ blood volume χ ( l-hematocnt) 
g _
 body-weight 
(blood volume was determined from a nomogram, based on sex, 
weight and height, with a correction for overweight (12)). 
During a steady state the turnover rate is equal to the rate 
of secretion in the plasma. 
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In all seven type III patients except one the turnover rate 
of plasma TG and VLDL-TG was determined. In most normal subjects 
and type IV patients and in one type III subject only the turn-
over rate of the plasma-TG was determined, because of the close 
similarity between the turnover rates of plasma TG and VLDL-TG 
(13, 14). 
The turnover was measured over a 7 hour time period. Recent-
ly, Zech et al (15) have demonstrated that after 15 hours the 
curve shows a slower decay, which was explained, using a multi-
compartmental analysis, as the result of a slowly turning-over 
precursor compartment. They considered it as unlikely that 
single exponential analysis, using only the steep part of the 
decay curve would provide an accurate estimate of the VLDL-TG 
turnover. However, the turnover rates of VLDL-TG in normo- and 
hypertnglyceridemic subjects as calculated from multicompart-
mental analysis, appear to correlate significantly with those, 
obtained by single exponential analysis of the same experiments 
(16). There was also a good agreement with the results of others 
(17) and our results in normal subjects using single exponential 
analysis. Neglection of the slow tail by measuring only for a 7 
hour time period does not seem to influence the results, at 
least in normal subjects and type IV patients. 
However, in type III patients with two populations of VLDL 
(normal or preß-VLDL and VLDL-remnants or ß-VLDL), the slow tail 
is mainly caused by slowly turning-over ß-VLDL-TG (15). The 
steep part of the decay curve results from fastly turning-over 
preß-VLDL-TG as well as from slowly turning-over ß-VLDL-TG. Be-
cause of the rather large amount of slowly turning-over ß-VLDL-TG 
m type III patients interpretation of only the fastly decaying 
portion of the curve results in an overestimation of the FCR and 
thus of the turnover rate of total VLDL-TG, as was pointed out 
by Zech et al (15). On the other hand, the fastly decaying por-
tion of the curve assesses the FCR of preß-VLDL-TG, with the 
possibility of underestimation, because of the contribution of 
the slowly turning-over ß-VLDL-TG. From the data of Zech et al 
(15, equation 4 and figure 7) we have calculated the size of 
this underestimation (table 2). From the ratio cholesterol/TG 
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Table 2. The influence of the relative amounts of preß- and ß-VLDL-TG on the 
parameters in VLDL-TG turnover studies 
VLDL-chol preß-VLDL-TG fraction of TG correction fac- correction factor 
VLDL-TG total VLDL-TG cleared as tor for FCR of for turnover rate 
preß-VLDL-TG preß-VLDL-TC, of preß-VLDL-TG 
1 2 3 4 5 
0.12 
0 .23 
0 .46 
0 .68 
0 .91 
1.14 
1.36 
1.59 
1.82 
1.00 
1.00 
0 .99 
0 .82 
0 .65 
0 .52 
0 .37 
0 .20 
0 .03 
1.00 
1.00 
1.00 
0 .98 
0 .95 
0 .91 
0 .84 
0 .70 
0 .20 
1 
1 
1.05 
1.18 
1.45 
1.81 
2 .44 
3.70 
8 .20 
1 
1 
1.05 
0 .97 
0 .94 
0 .94 
0 . 9 0 
0 .74 
0 . 2 5 
1. ratio VLDL-cholesterol/VLDL-TG, both in mmol/1 (arbitrarily chosen 
figures) 
2. fraction of VLDL-TG, present as preß-VLDL-TG (derived from fig. 7 in 
Zech et al (15), considering a cholesterol/TG ratio of 0.41 for preß-
VLDL and of 1.89 for ß-VLDL (15)) 
3. fraction of VLDL-TG, cleared as preß-VLDL-TG (derived from fig. 7 in 
Zech et al (15), considering FCR of preß-VLDL-TG is tenfold FCR of 
ß-VLDL-TG (15)) 
4. correction factor for the FCR of preß-VLDL-TG, derived from Eq. 4 in 
Zech et al (15) 
5. correction factor for the turnover rate of preß-VLDL-TG (product of the 
factors in column 2 and 4) . 
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in the VLDL the fraction of VLDL-TG, present as preß-VLDL-TG, 
has been calculated, considering that the cholesterol/TG ratio 
is 0.41 in preß-VLDL and the ratio is 1.81 in S-VLDL (15) 
(column 2). The fraction of total VLDL-TG, cleared by the preß-
VLDL pathway is mentioned in column 3. With equation 4 in Zech 
et al (15): 1 + (pcR B-VLDL-TcT^ "1) X (fractlon o f VLDL-TG, 
cleared as ß-VLDL), the FCR of preß-VLDL-TG has been calculated 
from the FCR of VLDL-TG. Because usually pCR of B-VLDL-TG"TG = 10 
(15), column 4 gives the size of underestimation of the FCR of 
preß-VLDL-TG, when single exponential analysis is used. The 
turnover rate is the product of the FCR and the plasma pool. 
Because the plasma pool of preß-VLDL-TG is smaller than that of 
total VLDL-TG, the factor to calculate the turnover rate of 
preß-VLDL-TG, would be equally smaller; this correction factor 
is given in column 5 and is the product of the factors in the 
columns 2 and 4. From these data, it can be concluded that 
interpretation of the fastly decaying portion of the curve 
without correction gives a considerable underestimation of the 
FCR of preß-VLDL-TG, but a good estimation of the turnover rate 
of preß-VLDL-TG, unless the ratio cholesterol/TG m VLDL is 
greater than 1.50, in which case an overestimation of the turn-
over rate of preß-VLDL-TG occurs. In other words: with single 
exponential analysis the apparent turnover rate of total VLDL-TG 
m type III patients with a cholesterol/TG ratio m the VLDL-
fraction less than 1.50, is an estimation of the real turnover 
rate of preß-VLDL-TG, because the underestimation by the deter-
mination of the FCR of total VLDL-TG (by the presence of ß-VLDL-
TG) is compensated by the overestimation of the preß-VLDL-TG 
plasma pool. 
A ratio cholesterol/TG in the VLDL of more than 0.92 is 
diagnostic for type III HLP (9). All our type III patients 
except one, had a ratio between 0.92 and 1.50. In these the 
apparent turnover rate of total VLDL-TG, calculated from single-
exponential analysis, is a good estimation for the real turnover 
rate of preß-VLDL-TG. However, in patient 2 with a cholesterol/ 
TG ratio in the VLDL of 2.35, the turnover rate of preß-VLDL is 
overestimated. 
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Determination of serum lipids and lipoproteins 
Blood samples were obtained by venepuncture after an over­
night fast. Cholesterol was determined by an enzymatic method 
(18) and triglycerides by a semi-automated colorimetrie method 
(19). The methods for separation and determination of VLDL by 
ultracentrifugation and the method for electrophoresis on 
agarose have been described previously (20, 21). The apoprotein 
Ε-subspecies of the VLDL were determined with the technique of 
analytical iso-electric focusing, as described in chapter 3. 
Statistical analysis 
All data are given as mean + 1 standard deviation. For 
paired results Student's t-test was used to test the differences 
for significance. For differences between groups the Wilcoxon-
test was used. 
RESULTS 
The turnover rate of plasma- en VLDL-TG was measured in 6 
type III patients. In the seventh patient only the turnover rate 
of plasma-TG was determined. The results are summarized in table 
3. The mean turnover rate of the VLDL-TG in 6 patients was 
18.1+4.8 pmol.kg .h , at a mean VLDL-TG concentration during 
the measurement of 5.29+2.81 mmol/1. 
The turnover rate of VLDL-TG in these patients was almost 
equal to that of plasma-TG. The mean turnover rate of plasma-TG 
in the 7 type III patients was 19.3+7.8 ymol.kg- .h~ , at a 
mean plasma-TG concentration of 5.93+2.87 mmol/1. The mean turn­
over rate in type III patients was significantly higher than in 
15 normal subjects (10.2+3.1 pmol.kg" .h_ ) (p<0.01) with a mean 
plasma-TG level of 1.14+0.32 mmol/1, although there was some 
overlap (table 3). 
In type IV patients the turnover rate did not differ sig­
nificantly from that of the type III patients: 20.1+8.7 pmol. 
kg .h , with values in and above the normal range; the mean 
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Table 3. The fractional catabolic rate (FCR) and the turnover rate of plasma- and VLDL-tnglycerxdes (V and 
V ) of patients with type III hyperlipoproteinemia 
VLDL~TG 
Patient 1 2 3 4 5 6 mean+SD 7 mean+SD normal type IV 
n=6 (range) subjects patients 
n=7 n=15 n=9 
plasma TG 3.93 7.06 3.45 4.67 11.50 7.07 6.28+2.99 3.84 5.93*+2.87 1.14+0.32 6.32+1.27 
(mmol/1) (3.45-11.50) (0.65-1.92) (5.00-8.30) 
FCR 0.11 0.12 0.11 0.12 0.09 0.05 0.10+0.03 0.11 0.10+0.02 0.25+0.06 0.09+0.04 
(h"1) (0.05-0.12) (0.14-0.35) (0.03-0.12) 
V 15.8 24.5 11.9 21.1 33.6 11.9 19.8+8.4 16.0 19.3*+7.8 10.2+3.1 20.1+8.7 
(pmol.kg-1.!!-1) (11.9-33.6) (6.0-15.0) (8.0-32.5) 
IT § 
VLDL-TG 3.04 5.98 2.71 3.65 10.17 6.21 5.29+2.81 n.d. 
(mmol/l) 
FCR 0.14 0.12 0.15 0.12 0.08 0.07 0.11+0.03 n.d. 
(h"1) 
V,„„r m^ 15.8 21.8 13.7 16.7 26.1 14.5 18.1+4.8 n.d. VLDL-TG — 
(pmol.kg .h ) 
*p<0.01 versus normal subjects,- not significant versus type IV patients 
ginean of 9 values during turnover measurement 
not determined 
plasma-TG concentration was almost similar to that of the type 
III patients: 6.32+1.27 mmol/1 (table 3). 
DISCUSSION 
We investigated the possible contribution of VLDL-over-
production to the pathogenesis of type III HLP. Usually, the 
production rate of VLDL is estimated by turnover studies during 
a steady state, after labeling of VLDL-TG or apoproteins. These 
methods have their limitations in practical use and interpreta-
tion. Because of its relative simplicity we chose to estimate 
the production rate of TG with the endogenous 2- H-glycerol 
labeling technique (10). The validity and reliability of the 
radioglycerol method have been discussed (13, 14) and questioned 
(22); however, the method gives data comparable to those ob-
tained by the lipolytic rate procedure and the VLDL-apoB turn-
over studies (23, 24). 
Most studies with the radioglycerol method were done over 
a 7 to 10 hour time period. In the present study the measure-
ments were carried out over 7 hours. Recently, Zech et al (15) 
have shown that after 15 hours a slow component of the curve 
appears, which is explained as a result of a slowly turning-
over precursor compartment, using multicompartmental analysis. 
Besides, m type III patients the turnover of slowly turning-
over ß-VLDL-TG or VLDL-remnants contribute also to the slow 
tail in the curve. Neglecting this portion of the curve in 
experiments in these patients, could result m an overestimation 
of the runover rate of VLDL-TG. However, the apparent turnover 
rate of the VLDL-TG, calculated from the early portion (7 hours) 
of the curve, gives a fair estimation of the real turnover of 
the fastly turning-over preß-VLDL-TG, even in type III patients 
(cf methods). Only when the ratio cholesterol/TG in the VLDL-
fraction is more than 1.50, indicating a rather large amount of 
VLDL-remnants in the VLDL-fraction, the turnover rate of the 
preß-VLDL-TG is overestimated. When in type III patients as m 
normal subjects (5, 25, 26) the bulk of VLDL-remnants is derived 
from preß-VLDL, the turnover rate of preß-VLDL-TG is a better 
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estimation of the VLDL-production than the turnover rate of 
total VLDL-TG. 
The mean value for the VLDL-TG-production in 7 type III 
patients was significantly higher than that in a control group, 
although there was some overlap. Only in one patient with a 
rather high cholesterol moiety in the VLDL-fraction, the VLDL-
TG-production has probably been overestimated. These results 
suggest that an increased VLDL-TG-synthesis is contributing in 
the pathogenesis of type III HLP. 
This observation is in agreement with that of Berman et al 
(5), who used the VLDL-apoprotem В method and found an in­
creased VLDL-secretion m 3 untreated type III patients and in 
1 patient treated with Clofibrate. On the other hand, Packard 
et al (27) using the same method, reported a normal VLDL-turnover 
in type III patients. Chait et al (4) studied type III and type 
IV patients with comparable mean VLDL-apoprotem В concentra­
tions. The turnover rate of VLDL-apoprotein В was lower in type 
III patients than in type IV patients. They gave no data about 
normal subjects, but the values for the VLDL-apoB turnover of 
the type III patients were in the same range as those of normal 
subjects, published afterwards (28). We found that the VLDL-TG-
production in type III and IV patients with comparable mean 
serum TG, was m the same range. Thus, it is likely that as in 
type IV patients, an increase in VLDL-TG-secretion contributes 
to the development of the hyperlipemia. This would be in agree­
ment with conclusions from studies of bile composition and bile 
acid kinetics m type III patients (29). The bile acid synthesis 
was increased similar to findings in type IV HLP patients (14). 
Because of the known correlation between the synthesis of VLDL-
TG and of bile acid (14), this also suggests an enhanced VLDL-
TG-production in type III HLP. Of course, the specific type III 
lipoprotein pattern cannot be explained solely by the increase 
in VLDL-production. 
So, between the various studies of type III HLP there are 
differences concerning the production rate of VLDL. One explana­
tion for this may be the difference in methods to estimate the 
VLDL-production. Perhaps there is just an overproduction of 
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triglycerides, whereas the production of VLDL-apoprotein В is 
normal. A second explanation may be differences in body-weight 
(16). Our type III and IV patients and control subjects did not 
differ significantly in body-weight, but the number of subjects 
was small. No correlation could be demonstrated between body-
weight and VLDL-TG-production in our type III patients. Three 
out of five patients of Berman et al (5) were obese. The type 
III patients of Chait et al (4) had a normal body-weight; of 
their type IV patients and the patients of Packard et al (27) 
the body-weights were not mentioned. In general, obesity goes 
with an increased VLDL-production (16). The well known good 
response of the lipid values in type III patients to a calorie-
restricted diet (1) could be due to a decrease of the VLDL-
synthesis. 
In type III HLP, a disturbance in the conversion of VLDL-
remnants to LDL has been demonstrated by several investigators 
(2, 3-5, 27). Using the radioglycerol method with a rather small 
dose of radioactivity we were not able to study this conversion. 
The results of all metabolic studies in type III HLP are in 
agreement with the hypothesis, that this disorder is based on 
a disturbance in conversion of VLDL-remnants to LDL, whether or 
not m combination with an increased VLDL-production. The VLDL-
TG-production could be increased by factors as familial pre­
disposition for HLP (28), obesity (16), carbohydrate-rich diet 
(30) or alcohol (31). There are also indications that a defect 
in the structure of the VLDL may be the underlying cause of type 
III HLP. The VLDL contain an increased amount of apoprotein E 
(7). Recently, Utermann et al (6) demonstrated a deficiency of 
the apoprotein E-3 moiety m VLDL. However, this was not specific 
for type III HLP. They postulated that a genetically determined 
deficiency of apoprotein E-3 gives a disturbance in the conver­
sion of VLDL-remnants to LDL, resulting in an accumulation of 
VLDL with 3-mobility. Not in all cases apoprotein E-3 deficiency 
results in a type III HLP. An increased VLDL-production as a 
consequence of above mentioned factors, as in most of our 
patients, could be the additional factor. 
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CHAPTER 7 
A STUDY OF THE HYPOLIPIDEMIC EFFECT ΟΓ CLOFIBRATE IN 
TYPE III HYPERLIPOPROTEINEMIA 
119 
ABSTRACT 
Patients with type III hyperlipoproteinemia respond well to 
therapy with diet, in some cases m combination with Clofibrate. 
The influence of Clofibrate on the production of very low den-
sity lipoproteins (VLDL) was studied by measurement of the turn-
over rate of VLDL-tnglycerides. The mean (+SD) turnover values 
in 4 type III patients decreased from 17.2+3.2 before to 9.0+1.7 
pmol.kg .h during treatment. 
Clofibrate induced changes in lipoprotein fractions were 
followed by frequent determinations during the first week of 
treatment. The 9 type III patients showed the same response: a 
considerable fall of serum- and VLDL-tnglycerides, serum cho-
lesterol and VLDL-cholesterol, but a transitory and significant 
rise of LDL-cholesterol. 
These data suggest that in patients with type III hyper-
lipoproteinemia Clofibrate inhibits the VLDL-production and 
stimulates the conversion of VLDL and VLDL-remnants to LDL. 
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INTRODUCTION 
Type III hyperlipoproteinemia (HLP), a disorder with a 
strong predisposition for cardiovascular disease and occurrence 
of xanthomas, is in contrast with some other kinds of HLP emi-
nently treatable. Xanthomas have been reported to disappear (1). 
As treatment a calorie-restricted diet is indicated, which may 
be combined with Clofibrate when the lipid-lowenng effect of 
diet alone is insufficient (2). The pathogenesis of type III HLP 
has not been fully elucidated, but there is evidence for a dis-
turbance in the removal of remnants of very low density lipo-
proteins (VLDL) (3), probably often in combination with an 
overproduction of VLDL (4 and chapter 6). 
Most studies on the mode of action of Clofibrate were done 
in normo- and hypertriglycendemic (type IV) subjects: in some 
studies a decreased synthesis of triglycerides (TG) was sugges-
ted (5-7), in an other study an increased clearance of TG was 
found (8) during administration of Clofibrate. There are also 
indications that Clofibrate increases the lipoprotein-lipase 
activity in skeletal muscle (9), adipose tissue (10) and post-
heparin plasma (11). The mode of action of Clofibrate in type 
III HLP has not been studied thoroughly. Berman et al (4) showed 
in one patient a reduction in VLDL-apoB synthesis. 
We studied the influence of Clofibrate on the VLDL-produc-
tion in type III HLP, by measurement of the turnover of VLDL-TG. 
Also, frequent determinations of the lipoprotein fractions were 
performed in order to obtain information concerning Clofibrate 
induced changes in the conversion of VLDL and remnants to LDL. 
MATERIALS AND METHODS 
Patients 
This study concerns 10 patients with type III HLP, 7 males 
and 3 females. Table 1 comprises the clinical and biochemical 
features. The ratio between VLDL-cholesterol and serum TG and 
between VLDL-cholesterol and VLDL-TG (expressed in mmol/1) was 
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to 
Table 1. Clinical and biochemical features of the patients with type III hyperlipoproteinemia 
Patient 1 10* 
Sex 
Age (years) 
Weight (kg) 
Relative weight (%) 
Xanthomatosis 
Ischaemic heart disease 
Peripheral vascular disease 
Serum cholesterol (chol)(mmol/1) 12.90 10.98 23.18 7.79 9.32 10.49 11.1 
M 
63 
84 
126 
+ 
M 
47 
69 
110 
_ 
F 
53 
67 
135 
+ 
M 
62 
67 
109 
_ 
M 
57 
68 
107 
_ 
M 
41 
83 
119 
+ 
F 
66 
58 
116 
F 
67 
69 
130 
M 
50 
76 
121 
+ 
M 
31 
101 
162 
Serum triglycerides (TG)(mmol/1) 4.82 
VLDL-chol (mmol/1) 
VLDL-TG (mmol/1) 
VLDL-chol/serum TG 
\LDL-chol/VLDL-TG 
3-VLDL 
Apoprotein E-3 deficiency 
7.06 
3.55 
1.46 
1.99 
4.55 8.42 3.50 5.38 3.88 
5.06 16.23 3.00 4.74 4.86 
3.86 6.91 2.26 5.03 3.41 
1.11 1.93 0.86 0.88 1.25 
1.31 2.35 1.33 0.94 1.42 
+ + + + + 
If 
8 
5.13 
6.00 
4.08 
1.17 
1.47 
+ 
+ 
11 .45 
2.65 
4.43 
1.80 
1.67 
2.46 
+ 
+ 
11.35 
6.96 
8.36 
5.97 
0.94 
1.20 
+ 
+ 
12.00 
7.98 
8.76 
6.30 
1.10 
1 .39 
+ 
+ 
participating in turnover study 
apoprotein E-3/E-2 ratio below 0.30 
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in all patients more than 0.69 and 0.92, respectively; both are 
considered as establishing type III HLP (12, 13). In all patients 
VLDL had ß-mobility on agarose-electrophoresis while on analyti-
cal isoelectric focusing, the VLDL of all patients were lacking 
apoprotein E-3. In seven patients a familial form of type III 
HLP was demonstrated. Secondary forms of type III HLP were ex-
cluded. None of the patients had clinical diabetes mellitus. As 
a reference group for the turnover study we used 15 normal sub-
jects (11 males and 4 females, mean age 46+12 years, mean rela-
tive body-weight 117+19%). The patients, participating in the 
turnover studies, did not differ significantly from the normal 
subjects m age and body-weight. The relative body-weight was 
calculated as the ratio between the actual weight χ 100% and 
the ideal weight, based on Metropolitan Life Insurance Tables 
(1959). All subjects had given their informed consent to the 
study. 
The design of the study 
We studied the influence of Clofibrate on the production 
rate of VLDL and on the conversion of VLDL and VLDL-remnants to 
LDL. Therefore, the turnover rates of plasma TG and VLDL-TG 
before and during treatment with Clofibrate were compared. The 
labeling of triglycerides with a rather low dose of H-glycerol, 
as was used in this study, is not suitable for studying the con­
version of VLDL to LDL, as most of the label is split off during 
this process. For this purpose, use was made of the known fact 
that the half life of plasma LDL is more than tenfold longer 
than that of VLDL (14, 15). Therefore, acute changes m the con­
version of VLDL to LDL might result in temporary changes in the 
LDL-level, which can be detected by frequent measurement of 
lipoprotein levels. 
All patients were studied as outpatients. In our experience 
admittance of type III patients to the hospital usually results 
in a marked decrease of lipid values, despite the attempts to 
maintain their usual diet. During follow-up m our outpatient 
department the lipid values show less variation. For at least 
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two months prior to the study no drugs were used, which could 
influence the lipoprotein metabolism. The moderately fat re­
stricted diet remained unchanged. In 4 patients (no. 2, 3, 7 
and 10) the turnover rate of VLDL-TG was measured prior to 
treatment (these data have also been used m the study, de­
scribed in chapter 6). In all patients treatment with 2 grams 
Clofibrate, divided in 2 doses daily, was started. The lipopro­
tein fractions were determined in 9 patients (all except patient 
no. 10) as often as possible during the first week of treatment. 
After stabilisation of the lipid values the measurement of the 
turnover rate of VLDL-TG was repeated in the 4 patients. 
Measurement of the turnover rate of plasma- and VLDL-tnglyce-
rides 
To estimate the synthesis of VLDL the turnover rate of 
plasma- and VLDL-triglycendes were measured during a steady 
state, by means of the Η-glycerol method originally described 
by Farquhar et al (16). The detailed description and validation 
of this method has been given in chapter 6. 
Determination of serum lipids and lipoproteins 
Blood samples were obtained by venepuncture after an over­
night fast. Cholesterol was determined by an enzymatic method 
(17) and triglycerides by a semi-automated colorimetrie method 
(18). The methods for separation and determination of lipopro­
teins (VLDL, IDL, LDL, LDL2 and HDL) by ultracentrifugation and 
the method for electrophoresis on agarose have been described 
previously (19-21). The apoprotein Ε-subspecies of VLDL were 
determined with the technique of analytical isoelectric focusing 
as described in chapter 3. 
Statistical analysis 
All data are given as mean + standard deviation, unless 
otherwise indicated. Student's t-test was used to test the 
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differences of paired results for significance. For differences 
between groups the Wilcoxon-test was used. 
RESULTS 
Serum lipids and lipoprotein fractions before and during treat­
ment with Clofibrate 
In figure 1 a typical example of the course of the lipopro­
tein fractions during the initial days of therapy with Clofi­
brate is given. 
12 
10 
OL l m m o l / 1 ) 
| Clofibrate | ι 
_.^, 
; · \ 
! \ 
/V\ 
^ - ~ ^ 
'-PQ; 
pat 
V 
\._ 
ч 
\^_ 
ь^. 
ent а I I 
[ 
• tota I 
1 
1 
«VLDL 
I 0 L 
10 15 20 days 
Figure 1. Cholesterol levels in the lipoprotein fractions in 
patient 8 with type III HLP before and on treatment 
with Clofibrate (2 grams daily) . 
After 1 week of treatment the serum cholesterol level had fallen 
gradually to normal values, which was particularly a consequence 
of the lowering of VLDL-cholesterol. In contrast, LDL-choleste-
rol showed an initial increase on days 2 and 3 and later a de­
crease to below the starting value. The temporary increase of 
LDL-cholesterol appeared to be caused by a temporary increase 
of LDL ?-cholesterol. The other eight patients showed a similar 
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pattern. In table 2 the values of LDL-cholesterol during the 
initial 28 days of treatment are given. All showed an increase 
of LDL-cholesterol on the second and third day of treatment as 
compared to the starting value, and further, a decrease on the 
9th and 28th days. In figure 2 the mean courses of the lipopro­
tein fractions in all 9 patients is presented. 
C H O L ( m m o l / l ) 
I " clofiCrote ~ | 
•ln serum 
-J LDL 
-f« VLDL 
- ι LDL 2 
" J IOL 
- 1 HDL 
—ι 
TG ( m m o l / l ) 
6 
4 
2-
0 3 9 2Θ days 
Figure 2. Serum triglycerides and cholesterol levels in serum 
and in the lipoprotein fractions in 9 patients with 
type III HLP before and on treatment with 2 grams 
Clofibrate daily (mean +_ SEM) . 
p<0.05 versus last value before treatment. 
Serum-TG, serum cholesterol and VLDL-cholesterol were lowered 
significantly (p<0.05). However, LDL-cholesterol rose initially 
(on the third day p<0.001) and fell on the 28th day to a level, 
not different from the starting value. IDL-cholesterol did not 
14-
12 
ισ 
Ц 
2-
n . 9 
mean i SEM 
1 * 
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Table 2. LDL-cholesterol (mmol/1) before and on treatment with Clofibrate in patients with 
type III hyperlipoproteinemia 
patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
mean 
+ sd 
before 
3.72* 
5.06 
5.97 
3.14 
3.20 
2.71 
4.08 
5.09 
2.79 
3.97 
+ 1.16 
Clofibrate 
4.SB11 
5.18 
5.80 
3.20 
2.87 
4.46 
4.44 
5.66 
2.01 
4.24 
+ 1 .30 
on clc 
day 1 
-
-
7.51 
-
3.08 
-
3.87 
5.41 
3.31 
fibrate 
2 
-
-
8.36 
3.28 
3.21 
-
5.32 
6.55 
-
3 
5.73 
6.55 
7.55 
4.11 
3.49 
5.00 
4.69 
6.16 
3.82 
5.24§ 
+ 1.37 
4 
-
-
8 
3 
3 
-
-
5 
-
29 
86 
35 
70 
5 
-
-
-
3 
3 
-
3 
5 
-
59 
98 
73 
08 
9 
4.77 
4.21 
4.38 
3.02 
3.35 
4.18 
2.80 
3.48 
4.16 
3.82 
+ 0.67 
15 
3.33 
4.11 
-
2.37 
3.45 
-
2.24 
-
-
28 
3.58 
4.90 
3.26 
2.91 
3.54 
3.52 
2.82 
3.23 
3.76 
3.50 
+ 0.61 
*levels 4-50 days before start of therapy 
levels 1-5 days before start of therapy 
§ 
p<0.001 comparing with last value before start of therapy 
change significantly. As to LDL_-cholesterol, there was also an 
initial rise (p<0.05) and a subsequent fall on the 28th day. 
HDL-cholesterol did not change significantly in the first 28 
days of treatment with Clofibrate. 
The mean ratio between VLDL-cholesterol and serum TG de-
creased from 1.24+0.41 before therapy to 0.98+0.26 on the 28th 
day of treatment (p<0.01). The mean ratio between VLDL-choleste-
rol and VLDL-TG decreased from 1.60+0.58 to 1.38+0.4 2 (p<0.05). 
Thus, during treatment the VLDL-fraction remained still abnor-
mally rich m cholesterol. 
The turnover rate of plasma- and VLDL-triglycendes before and 
during treatment with Clofibrate 
Table 3 shows the results of the measurement of the turn-
over rate of plasma TG and VLDL-TG. The duration of therapy with 
Clofibrate before the second measurement varied from 6 to 37 
weeks. In 2 of the 4 patients there was a small decrease in 
body-weight. In all patients there was a marked fall m plasma 
TG and VLDL-TG. The turnover of plasma TG and VLDL-TG, elevated 
in 3 of the 4 patients before treatment, decreased in all to 
levels in the normal or nearly normal range. The fractional 
catabolic rate increased in all patients. 
DISCUSSION 
Type III HLP is well amenable to treatment with diet and 
Clofibrate. Till now the mode of action of Clofibrate is un-
certain. Most studies have been done in normo- and hypertn-
glycendemic (type IV) patients, suggesting various mechanisms: 
decreased TG turnover, increased TG clearance and increased 
lipoprotein lipase activity. The purpose of this study was to 
determine the effect of Clofibrate on the production rate of TG 
and on the conversion of VLDL and remnants to LDL in type III 
HLP. Therefore, the turnover rates of TG and of VLDL-TG were 
measured before and during treatment with Clofibrate. Use was 
made of the radioglycerol method, because of its relative sim-
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Table 3. Effect of Clofibrate on plasma triglycerides (TG), 
VLDL-TG, fractional catabolic rate (FCR) and turnover 
rate of plasma TG (V^) and VLDL-TG (VVLDL_TG) m 
patients with type III hyperlipoproteinemia. 
patient 
mean TG* 
(mmol/1) 
FCR 
(h"1) 
VTG 
(pmol/kg. h) 
a" 
b 
a 
b 
a 
b 
2 
3.93 
2.06 
0.11 
0.17 
15.8 
14.2 
3 
7.06 
1.98 
0.12 
0.15 
24.5 
10.1 
7 
4.67 
2.36 
0.12 
0.17 
21.1 
15.1 
10 
7.07 
1.67 
0.05 
0.15 
11.9 
7.7 
normal subjects (n=15) 
mean+SD 
1.14+0.32 
0.25+0.06 
10.2+3.1 
(range) 
(0.65-1.92) 
(0.14-0.35) 
(6.0-15.0) 
mean VLDL-TG* a 3.04 5.98 3.65 6.21 
(mmol/l) b 1.49 1.00 1.48 1.15 
FCR 
(h"1) 
a 0.14 0.12 0.12 0.15 
b 0.19 0.23 0.16 0.22 
VLDL-TG 
(ymol/kg.h) 
a 
b 
15.8 
11.5 
21.8 
7.9 
16.7 14.5 
8.9 7.7 
body-weight 
(kg) 
a 69 
b 69 
67 
64 
58 
56 
101 
102 
VLDL-chol 
VLDL-TG a 1.31 2.35 1.47 1.39 
b 0.94 1.76 1.12 1.30 
duration of 6 
therapy (weeks) 
37 26 
U 
•mean of 9 values during turnover measurement 
before (a) and during (b) therapy with Clofibrate 
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plicity. The reliability and validity of this method have been 
discussed (22, 23) and questioned (24); however, this method 
gave data comparable to those obtained by the lipolytic rate 
procedure and VLDL-apoB turnover studies (25, 26). 
In the present study the measurement with the radioglycerol 
method was carried out over 7 hours, as in most other studies. 
In this way a slow component of the curve, caused by a slowly 
turning-over precursor component, as recently shown by Zech et 
al (27), is neglected. In chapter 6 we discussed the effect of 
neglection of this slow tail on the calculation of the VLDL-
turnover rate. Briefly, in normo- and hypertriglyceridemic 
patients a significant and positive correlation between paired 
turnover data has been reported, calculated either with single 
exponential analysis of the curve (over a 7 to 10 hour time 
period) or multicompartmental analysis (over 48 hours). However, 
in type III patients the slow tail is mainly caused by slowly 
turning-over ß-VLDL-TG. This cannot be neglected when the turn-
over of total VLDL-TG is measured. Intentionally neglecting the 
slow component gives an overestimation of the fractional cata-
bolic rate and of the turnover rate of total VLDL-TG. However, 
it can be argued that the apparent turnover rate of the total 
VLDL-TG, calculated from the early portion of the curve gives 
a fair estimation of the real turnover rate of the fastly 
turning-over preß-VLDL-TG, even in type III patients. This 
holds only when there is not a too large amount of ß-VLDL or 
VLDL-remnants, indicated by a cholesterol/TG ratio in the VLDL-
fraction of more than 1.50. Assuming that in type III patients, 
as in normal subjects, the bulk of VLDL-remnants or ß-VLDL are 
derived from preß-VLDL (4, 28, 29), the turnover rate of preß-
VLDL-TG is a better estimation of the TG production rate in 
type III patients than that of total VLDL-TG. 
In 4 type III patients we observed that Clofibrate lowered 
the turnover rate of VLDL-TG from elevated values to normal or 
nearly normal values. In one of these patients, the turnover 
rate of VLDL-TG could have been overestimated because the ratio 
cholesterol/TG in the VLDL was 2.35. Indeed, this patient had 
the highest turnover rate. During treatment, the ratio decreased 
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to 1.76, and the overestimation of the turnover rate is now 
reduced. So, in this patient a part of the decrease in the turn-
over rate could have been the result of a decrease in over-
estimation. However, there remains sufficient evidence for the 
conclusion that the production rate of VLDL-TG in type III HLP 
is lowered by Clofibrate. This could agree with the observation 
of Herman et al (4), who showed a decrease in VLDL-apoB turnover 
rate in one type III patient. However, the body-weight of that 
patient decreased with 8 percent. There was only a small loss in 
weight in two of our 4 patients. 
The rapid fall of the VLDL lipids in the first few days of 
treatment and the large difference in degradation rate between 
VLDL and LDL offered the opportunity to get information, in an 
indirect way, about a possible change in the rate of conversion 
of VLDL and VLDL-remnants to LDL, induced by Clofibrate. Fre-
quent determinations showed a transitory rise in LDL-cholesterol 
while at the same time VLDL-cholesterol fell steeply. In our 
opinion, the only way to explain this phenomenon is by assuming 
an increased rate of conversion of VLDL and VLDL-remnants to 
LDL, induced by Clofibrate. Theoretically, there are of course 
other possible explanations, such as a transitory decrease in 
LDL catabolism or change in LDL composition, but they are very 
unlikely. The subsequent decrease m LDL-cholesterol may be 
considered as a consequence of the diminishing supply of VLDL. 
With the VLDL-apoprotein B-method an increased conversion of 
VLDL to LDL has not been found (4). 
Changes m lipoprotein concentrations during treatment with 
Clofibrate were also studied by others (30, 31). They did not 
find a rise of LDL-cholesterol in type III patients and con-
cluded that Clofibrate did not improve the conversion of VLDL 
to LDL. However, they measured the lipoprotein fractions before 
and some weeks after the start of treatment and must have missed 
the rise of LDL in the first few days. 
Our results demonstrate that the therapeutic effect of 
Clofibrate m type III HLP is probably due to two actions: an 
inhibition of VLDL-TG-production and a stimulation of the con-
version of VLDL and VLDL-remnants to LDL. Clofibrate does not 
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fully remove the defect in the metabolism of VLDL-remnants: the 
VLDL-fraction remains abnormally rich in cholesterol and the 
electrophoretic features (VLDL with slow mobility) remain detec-
table, as we showed earlier (21). 
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CHAPTER 8 
A STUDY OF THE HYPOLIPIDEMIC EFFECT OF ESTROGEN IN TYPE III 
HYPERLIPOPROTEINEMIA 
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ABSTRACT 
The paradoxically hypolipidemic effect of estrogen in type 
III hyperlipoproteinemia (HLP) was studied m 2 postmenopausal 
women and 2 men. Estrogen was given as ethinylestradiol 1 \iq/ 
kg/day during 15 days. All subjects showed the same hypolipid­
emic response. Estrogen did not appreciably change the turnover 
rate of very low density lipoprotein (VLDL) triglycerides, 
3 
measured with the Η-glycerol method before and on the 15th 
day of use, m contrast with the known increasing effect m nor­
mal subjects and type IV HLP patients. Frequent determinations 
during the first week of treatment showed a gradual decrease of 
serum cholesterol, serum triglycerides, VLDL-cholesterol and 
VLDL-triglycendes. There was no temporary increase m low 
density lipoprotein (LDL) cholesterol, in contrast with previous 
observations with Clofibrate. The data suggest that the hypo­
lipidemic effect of estrogen in type III HLP is the result of 
an improved catabolism of VLDL-remnants by direct degradation 
without changes in VLDL-production. 
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INTRODUCTION 
Type III hyperlipoproteinemia (HLP) is a familial distur-
bance in the metabolism of lipoproteins. The very low density 
lipoproteins (VLDL) have an abnormally high cholesterol content 
and a lower electrophoretic mobility than normal (1). There is 
an accumulation of VLDL-remnants (Sf 20-100), which are an inter-
mediate product in the conversion of VLDL to low density lipopro-
teins (LDL) (2, 3). The disorder is probably based on a distur-
bance in the catabolism of VLDL-remnants (4), in some cases in 
combination with an overproduction of VLDL saturating the 
metabolic pathway (5 and chapter 6). The VLDL are deficient of 
apoprotein E-3 (6) and the defect in removal of VLDL-remnants 
seems related to this deficiency (7). 
In normal subjects and patients with type IV HLP treatment 
with estrogen increases plasma triglycerides (TG) as a con-
sequence of an increased secretion by the liver (8-10). However, 
m type III HLP patients estrogen decreases plasma lipids, while 
the lipid composition and electrophoretic mobility of the VLDL 
changes to normal (4, 11-13). The mode of action of estrogen in 
type III HLP is uncertain. An improvement of the impaired 
catabolism of VLDL-remnants is suggested (4). The purpose of 
this study was to establish the mode of action of estrogen in 
type III HLP, particularly the influence on the VLDL-production 
by measurement of the turnover rate of VLDL-TG and on the con-
version of VLDL and remnants to LDL by frequent determinations 
of the lipoprotein fractions. 
MATERIALS AND METHODS 
Patients 
The study concerned 4 patients with type III HLP, 2 post-
menopausal women and 2 men. Table 1 gives a survey of the 
clinical and biochemical features. The ratio between VLDL-
cholesterol and serum TG and between VLDL-cholesterol and VLDL-
TG (expressed in mmol/1) were respectively more than 0.69 and 
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Table 1. Clinical and biochemical features of the patients with type III hyperlipoproteinemia 
Patient 1 2 3 4 
Sex 
Age (years) 
Relative weight (%) 
Xanthomatosis 
Ischaemic Heart Disease 
Peripheral Vascular Disease 
Serum cholesterol (chol) (mmol/1) 
Serum triglycerides (TG) (mmol/l) 
VLDL-chol (mmol/1) 
VLDL-TG (mmol/l) 
VLDL-chol/serum TG 
VLDL-chol/VLDL-TG 
e-VLDL 
Apoprotein E-3 deficiency* 
F F 
67 59 
110 137 
+ 
M M 
50 31 
112 163 
8.29 13.45 9.23 11.67 
3.12 10.06 3.44 8.49 
2.63 9.59 3.19 9.11 
1.95 8.84 2.58 7.12 
0.84 0.95 0.92 1.07 
1.35 1.08 1.24 1.28 
+ + + + 
+ + + + 
*Apoprotein E-3/E-2 ratio below 0.30 
0.92, both being considered as establishing type III HLP (14, 
15). The electrophoretic pattern was interpreted according to 
Demacker et al (16): all patients had a group 5 pattern (serum 
presented a widened 3 band with β and intermediate 0- preß 
migration and VLDL presented a normal preß band and an extra 
band with intermediate ß- preß migration). The VLDL of all 
patients were lacking apoprotein E-3 (6). All subjects had a 
familial form of type III HLP. Causes of secondary HLP could 
be excluded. None of the patients had clinical diabetes mellitus. 
As a reference group for the turnover studies we used 15 normal 
subjects (11 males and 4 females, mean age 46+12 years, mean 
relative body-weight 117+19%). The relative body-weight was 
calculated as the ratio between the actual weight χ 100% and 
the ideal weight, based on Metropolitan Life Insurance Tables 
(1959). All subjects had given their informed consent to the 
study. 
The design of the study 
The purpose of this study was to investigate the mechanism 
of the hypolipidemic effect of estrogen in type III HLP. There­
fore, we measured the turnover rate of plasma TG and VLDL-TG 
before and during treatment with estrogen. The labeling of TG 
with a rather low dose of Η-glycerol, as was used m this study, 
however, is not a suitable method for studying the conversion of 
VLDL to LDL, as most of the label is split off during this 
process. For this purpose, use was made of the known fact that 
the half life of LDL is more than tenfold longer than that of 
VLDL (17, 18). Therefore, acute changes in the conversion rate 
of VLDL to LDL might result in temporary changes in LDL-level, 
which can be detected by frequent measurement of lipoprotein 
levels in the initial days of treatment. In this way we have 
previously observed a temporary increase of LDL cholesterol in 
type III patients in the first days of treatment with Clofibrate, 
from which we inferred an increased conversion of VLDL to LDL 
(chapter 7). 
All subjects were studied as outpatients. In our experience 
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admittance of type III patients to the hospital usually results 
in a marked decrease of lipid values, despite attempts to main­
tain their usual diet. During follow-up in our outpatient clinic 
the lipid values show less variation. For at least 1 month prior 
to the study no drugs were used which could influence the metab­
olism of lipoproteins. None of the patients had ever used any 
hormonal medication. The moderate fat restricted diet remained 
unchanged. The turnover rate of plasma TG and VLDL-TG was 
measured some days before the start of treatment with estrogen 
and on the fifteenth day of treatment (the basal values of 
patient no. 2 and 4 have also been used m the study, described 
in chapter 6). Fasting lipoprotein levels were determined twice 
in the week before the start of treatment and on the initial 
five days, the 8th and the 15th day of treatment. In 2 patients 
analytical isoelectric focusing of VLDL-apoproteins was per­
formed before and during use. Estrogen was prescribed as ethinyl-
estradiol in a dose of 1 pg/kg/day for 15 days. 
Measurement of the turnover rate of plasma triglycerides and 
VLDL-triglycerides 
To estimate the synthesis of VLDL the turnover rate of 
plasma- and VLDL-TG were measured during a steady state, by 
means of the Η-glycerol method originally described by Farquhar 
et al (19). The detailed description and validation of this 
method has been given m chapter 6. 
Determination of serum lipids and lipoproteins 
Blood samples were obtained by venepuncture after an over­
night fast. Cholesterol was determined by an enzymatic method 
(20) and TG by a semi-automated colorimetrie method (21). The 
methods for separation and determination of lipoproteins (VLDL, 
IDL, LDL, LDL-,) by ultracentrifugation, for determination of 
HDL-cholesterol by precipitation and the method for electro­
phoresis on agarose were previously described (16, 22, 23). The 
isoforms of apoprotein E and the non-identical polypeptides of 
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apoprotein С of the VLDL were determined with the technique of 
analytical isoelectric focusing as described in chapter 3. 
All data are given as mean + 1 standard deviation. 
RESULTS 
Serum lipids and lipoprotein fractions before and during treat­
ment with estrogen 
In all 4 patients there was a decrease of serum cholesterol 
and serum TG. The individual lipid values before and on the 8th 
and 15th day of treatment with estrogen are mentioned m table 2. 
Table 3 shows the mean lipid values in the initial days of use. 
Male and female subjects with initially similar values had the 
same degree of decrease of serum lipids. In the first week of 
treatment there was already a marked fall in serum lipids. After 
two weeks serum cholesterol decreased to normal or high-normal 
values, but serum TG remained moderately elevated. The decrease 
of serum cholesterol and serum TG was particularly a consequence 
of the decrease of lipids in the VLDL-fraction. Mean IDL-
cholesterol and IDL-TG showed a slight increase as a result of 
a marked change in one patient. After 2 weeks of use of estrogen 
LDL-cholesterol had decreased in 3 patients and slightly in­
creased in one patient (table 4). Only patient no. 4 showed a 
temporary increase of LDL-cholesterol, but his initial LDL-
cholesterol was relatively low. In all other patients there was 
a gradual decrease with a single elevated value. The pattern of 
LDL-,-cholesterol was similar. There was a remarkable increase 
in HDL-cholesterol. The ratios between VLDL-cholesterol and 
serum TG and between VLDL-cholesterol and VLDL-TG decreased in 
all. Only in patient no. 1 the ratios were reduced to values 
below the diagnostic limit for type III HLP and no ß-VLDL was 
detectable anymore after 15 days of treatment in this patient. 
In the 3 other patients the VLDL-fraction was still abnormally 
cholesterol-rich after two weeks of treatment with estrogen. In 
two of these 3 subjects we restudied the electrophoretic pattern 
of VLDL: both of them kept ß-VLDL. 
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Table 2. Effect of estrogen on lipids and lipoprotein fractions in patients with type III 
hyperlipoproteinemia (mmol/1) 
chol TG VLDL 
chol 
VLDL 
TG 
IDL 
chol 
IDL 
TG 
LDL 
chol 
HDL 
chol 
VLDL chol VLDL chol ß-VLDL 
TG 
patient day 
VLDL TG 
15 
0* 
8 
15 
8.49 
5.31 
5.86 
0* 13.32 
8 10.09 
15 7.29 
0* 9.06 
8 6.89 
15 5.67 
11.47 
8.29 
7.36 
3.50 
2.16 
2.52 
9.36 
6.96 
4.68 
3.82 
2.47 
1.95 
7.91 
3.32 
5.36 
3.23 
0.89 
1.47 
2.43 
1.45 
1.63 
9.66 8.57 
6.29 5.68 
3.43 3.33 
3.49 1.87 
1.63 1.61 
1.33 1.10 
8.96 6.80 
4.42 2.73 
4.44 4.10 
1 .77 
0.89 
0.98 
0.42 
0.33 
n.d.1 
3.94 
2.57 
2.64 
1.33 
1 .85 
1 .75 
1.35 0.26 2.92 0.75 
1.22 0.34 2.77 1.03 
1.21 0.11 2.58 1.28 
1.41 0.05 4.77 0.98 
1.19 0.28 3.91 1.35 
0.84 0.17 2.70 n.d. 
0.12 0.36 1.65 0.87 
1.18 0.19 2.18 1.06 
0.78 0.36 1.93 0.99 
0.92 
0.41 
0.58 
1.03 
0.90 
0.73 
0.91 
0.66 
0.68 
1 .13 
1 .33 
0.83 
1 -
0. 
0, 
.33 
.61 
.90 
.13 
.11 
.03 
.22 
.01 
.21 
.32 
.62 
.08 
+ 
-
-
n.d 
n.d 
n.d 
+ 
+ 
+ 
+ 
n.d 
+ 
Chol = cholesterol; TG = triglycerides 
*Mean of the last two values, within a week before start of therapy with estrogen 
H 
n.d. not determined 
Table 3. Effect of estrogen on mean lipid levels in lipoprotein 
fractions in 4 patients with type III hyperlipopro­
teinemia (mmol/l) 
day 0 * 1 2 3 4 5 8 15 
Cholesterol 
(chol) 
Triglycerides 
(TG) 
VLDL chol 
VLDL TG 
IDL chol 
IDL TG 
LDL 2 chol 
HDL chol 
10. 
6, 
6. 
5. 
1. 
0. 
2. 
0. 
.59 
.15 
.34 
.17 
.16 
.27 
.09 
.98 
9. 
5. 
5. 
4, 
1. 
0. 
1. 
1. 
.88 
.90 
.72 
.88 
.16 
.25 
.83 
.01 
9. 
5, 
5, 
4, 
1. 
0. 
2. 
1. 
.63 
.69 
.39 
.52 
.18 
.30 
.01 
.05 
9. 
4, 
4, 
3, 
1 . 
η. 
2. 
1 . 
.25 
.82 
.44 
.71 
.50 
.cl.11 
. 14 
,17 
8. 
3 
3 
2 
1 
0, 
2. 
1 . 
.62 
.91 
.88 
.90 
.53 
.36 
.10 
11 
8, 
3 
3, 
2, 
1 . 
0. 
2. 
1. 
.30 
.63 
.56 
.88 
46 
.35 
.17 
.12 
7. 
3 
3, 
2, 
1 . 
0. 
1 . 
1 . 
.65 
.73 
.31 
.87 
12 
.29 
74 
32 
6 
3 
2 
2 
0. 
η , 
1 . 
η. 
.55 
.63 
.67 
.54 
.95 
.d. 
.51 
.d. 
*Mean of last two values within a week before start of therapy 
with estrogen 
n.d.: not determined 
Table 4. Effect of estrogen on LDL-cholesterol in patients with 
type III hyperlipoproteinemia (mmol/l) 
patient day 0 * 1 2 3 4 5 8 15 
1 3.94 3.27 3.28 3.73 3.30 3.39 2.57 2.64 
2 2.92 2.29 2.35 2.76 3.33 3.12 2.77 2.58 
3 4.77 3.97 4.66 4.63 4.41 4.31 3.91 2.70 
4 1.65 2.44 2.43 3.42 3.46 3.69 2.18 1.93 
*Mean of last two values, within a week before start of therapy 
with estrogen. 
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The turnover rate of plasma triglycerides and VLDL-triglycendes 
before and during treatment with estrogen 
Table 5 shows the results of the measurement of the turnover 
rate of plasma TG and VLDL-TG. After 2 weeks of treatment with 
estrogen mean plasma TG and VLDL-TG had decreased in all patients, 
but remained elevated. There was no appreciable change in turn­
over rate of plasma TG and VLDL-TG. Both female patients (no. 1 
and 2) had basal values above the normal range, both male 
patients (no. 3 and 4) within it. In all subjects there was a 
marked increase in the fractional catabolic rate. Two patients 
had a slight gain in body-weight (<3%) between the two measure­
ments. 
The apoprotein composition of VLDL before ard during treatment 
with estrogen 
In two patients (no. 2 and 4) the apoprotein composition 
of VLDL was studied. Because in the first week of treatment no 
or only a gradual change was seen, table 6 shows only the data 
before, on the 8th and on the 15th day of treatment. The apo­
protein ratio E-3/E-2 remained below 0.30, establishing a gross 
lack of apoE-3. In the relative propositions of the apoprotein С 
polypeptides no changes were seen. 
DISCUSSION 
Patients with type III HLP show a paradoxically hypolipid­
emic respons on treatment with estrogen in comparison with nor­
mal subjects and patients with type IV HLP (4, 11-13). This 
could be confirmed in this study. So far, the lipid-lowermg 
effect of estrogen had been observed in seven female type III 
HLP patients but only in one male patient. One other male patient, 
however, showed an aggravation of his HLP keeping all the bio­
chemical type III features (13). We studied 4 type III HLP 
patients, 2 males and 2 females, with similar basal lipid values. 
In all there was the same response: serum cholesterol decreased 
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Table 5. Effect of estrogen on plasmatriglycerides (TG), VLDL-
TG, fractional catabolic rate (FCR) and turnover rate 
of plasma TG (ν,„) and VLDL-TG (V,,T _,T __) in patients 
with type III hyperlipoproteinemia 
p a t i e n t 4 n o r m a l s u b j e c t s ( n = 1 5 ) 
m e a n + S D ( r a n g e ) 
m e a n TG* a 1 1 3 . 5 3 1 1 . 5 0 2 . 7 9 7 . 0 7 1 . 1 4 + 0 . 3 2 ( 0 . 6 5 - 1 . 9 2 ) 
( m m o l / 1 ) b 2 . 5 9 4 . 4 5 1 . 9 6 4 . 7 4 
FCR 
( h " 1 ) 
a 0 . 1 5 0 . 0 9 0 . 1 0 0 . 0 5 0 . 2 5 + 0 . 0 6 ( 0 . 1 4 - 0 . 3 5 ) 
b 0 . 1 7 0 . 1 7 0 . 1 9 0 . 0 8 
V, TG a 1 9 . 0 3 3 . 6 1 1 . 4 1 1 . 9 1 0 . 2 + 3 . 1 ( 6 . 0 - 1 5 . 0 ) 
( p m o l / k g . h ) b 1 6 . 2 2 7 . 5 1 5 . 7 1 2 . 0 
m e a n VLDL-TG* a 2 . 5 0 1 0 . 1 7 1 . 9 6 6 . 2 1 
( i r a n o l / 1 ) b 1 . 6 7 3 . 3 0 1 . 2 2 3 . 7 4 
FCR 
( h " 1 ) 
a 0 . 2 0 0 . 0 8 0 . 1 5 0 . 0 7 
b 0 . 2 4 0 . 2 3 0 . 2 7 0 . 1 4 
VVLDL-TG a 1 7 · 9 2Ъ-1 11-Ъ 1 4 · 5 
(ymol/kg.h) b 15.1 27.9 13.8 16.6 
body-weight 
(kg) 
a 
b 
56 
56 
76 
78 
70 
72 
101 
101 
VLDL-chol 
VLDL-TG a 1.31 0.99 
b 0.90 1.03 
1.24 1.39 
1.21 1.08 
*mean of 9 values during turnover measurement 
before (a) and during (b) therapy with estrogen 
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Table 6. Effect of estrogen on apoprotein E- and C-subspecies 
in VLDL of patients with type III hyperlipoproteinemia 
patient 
2 
4 
day 
0* 
8 
15 
0* 
8 
15 
area 
E3 
E2 
о.іг
11 
0.24 
0.21 
0.18 
0.08 
0.06 
— 
ratio 
CII 
CIII 
0.14 
0.13 
0.17 
0.14 
0.15 
0.15 
percent 
CII 
13 
11 
14 
12 
13 
13 
с 
of 
III-
21 
24 
23 
25 
33 
32 
tot 
•2 
al 
С 
apoC-
III-l 
42 
42 
43 
47 
40 
38 
•area 
CIII-0 
23 
22 
19 
14 
13 
17 
*Last value before start of therapy 
Value below 0.30 means gross lack of apoprotein E-3 
to normal or high-normal, serum TG decreased also, but remained 
elevated. The VLDL-fraction was less cholesterol-rich after 15 
days of treatment, but only in one patient the ratios between 
VLDL-cholesterol and serum TG and between VLDL-cholesterol and 
VLDL-TG decreased to the normal range and beta-VLDL was not 
detectable anymore. It is possible that after longer treatment 
the other patients also should get a normally composed VLDL-
fraction, as in most of the above mentioned observations in 
the literature. Anyhow, our results show convincingly that the 
effect of estrogen on plasma lipids is the same in men and women 
with type III HLP. 
We studied the influence of estrogen on the production rate 
of VLDL-TG in four type III HLP patients. Use was made of the 
radioglycerol method, because of its relative simplicity. The 
reliability and validity of this method have been discussed 
(24, 25) and questioned (26); however, this method gave data 
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comparable to those obtained by the lipolytic rate procedure 
and VLDL-apoprotein В turnover studies (27, 28). 
In the present study the measurement was carried out over 
7 hours, as m most other studies. In this way a slow component 
of the curve, caused by a slowly turning-over precursor compo­
nent, as recently shown by Zech et al (29), is neglected. In 
chapter 6 we discussed the effect of neglection of this slow 
tail on the calculation of the turnover rate of VLDL-TG. Briefly, 
in normo- and hypertnglyceridemic patients a significant and 
positive correlation between paired turnover data has been 
reported, calculated either with single exponential analysis 
of the curve (over a 7 to 10 hour time period) or multicompart-
mental analysis (over 48 hours) (30). However, m type III HLP 
patients the slow tail is mainly caused by slowly turning over 
ß-VLDL-TG. This cannot be neglected when the turnover rate of 
total VLDL-TG is measured. Intentionally neglecting the slow 
component gives an overestimation of the fractional catabolic 
rate and of the turnover rate of total VLDL-TG. However, it can 
be argued that the apparent turnover rate of total VLDL-TG, cal-
culated from the early portion of the curve gives a fair estima-
tion of the real turnover rate of the fastly turning-over pref1-
VLDL-TG, even in type III HLP patients. This holds only when 
there is not a too large amount of 3-VLDL or VLDL-remnants, 
indicated by a ratio between cholesterol and TG in the VLDL-
fraction of more than 1.50. Assuming that in type III patients, 
as in normal subjects the bulk of VLDL-remnants or ß-VLDL are 
derived from preg-VLDL (5, 31,32), the turnover rate of preß-
VLDL-TG is a better estimation of the TG production rate in type 
III HLP patients than that of total VLDL-TG. 
In the four patients the turnover rate of VLDL-TG did not 
change appreciably during treatment with estrogen. Because in 
all patients the ratio between cholesterol and TG in the VLDL-
fraction was below 1.50 as well before as well during the use 
of estrogen, there was no overestimation of the turnover rate. 
Therefore, the decrease in this ratio during treatment could 
not influence the outcome of the measurement. Thus, the conclu-
sion seems valid that estrogen has no influence on the turnover 
149 
rate of VLDL-TG in type III HLP patients, m contrast with the 
enhancing effect m normal and type IV HLP subjects (8-10). 
However, others reported an increase of the turnover rate of 
VLDL-apoprotein В (11) and of VLDL-TG (33) in one type III HLP 
patient during estrogen treatment. 
Because the hypolipidemic effect of estrogen is not the 
result of a decrease in VLDL-production, it has to be caused by 
an increased catabolism of VLDL-remnants. This agrees with other 
observations based on the kinetic changes in the lipoprotein 
lipase related TG removal (4). Corresponding to the results of 
our study with Clofibrate in type III patients (chapter 7) an 
increase of LDL-cholesterol would be expected in the first week 
of treatment with estrogen, if it is assumed that the greater 
part of the VLDL-remnants are converted to LDL. However, frequent 
determinations of the lipoprotein fraction in the first week of 
treatment showed only in one of the four patients a temporary 
rise in LDL-cholesterol, although m all patients in the same 
time a fall of VLDL-cholesterol was seen, similar to that with 
Clofibrate in our previous study. This could indicate that the 
improved catabolism of VLDL-remnants was the result of direct 
degradation and not of conversion to LDL. 
Studies in hypertriglyceridemic subjects have pointed out 
that a direct catabolism of VLDL and VLDL-remnants without con­
version to LDL occurs (5, 31, 32). The mechanism of the effect 
of estrogen on the catabolism of VLDL-remnants could be clarified 
by the results of recent studies, mostly done in animals, of the 
role of apoprotein E m lipoprotein metabolism. Apoprotein E 
appeared to be involved in the catabolism of VLDL-remnants by 
the liver through interaction with apoE-receptors on the hepato-
cyte membrane and it was suggested that the deficiency of apo­
protein E-3 is the basic disturbance in type III HLP leading to 
the removal defect of VLDL-remnants (7). The improved catabolism 
of VLDL-remnants during therapy with estrogen could be caused by 
a correction of the deficiency of apoprotein E-3. However, others 
demonstrated a persistent lack of this apoprotein during estrogen 
treatment (13) as we confirmed in this study. Otherwise, it could 
mean that estrogen induced an increase in number of hepatic apoE-
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receptors for the remnant particles, as was demonstrated in 
animal studies in vitro and in vivo (34, 35). Our results could 
indicate such a mechanism in man, but further studies for more 
direct evidence are needed. 
The relative proportions of the apoprotein С polypeptides 
in our patients did not change. This is in contrast with obser­
vations that the apoC-II/C-III ratio had decreased in normal 
women (36) and type III IILP patients (13) during treatment with 
estrogen. Differences in method and the short duration of treat­
ment of our patients might explain this finding. 
From these data it can be concluded that the hypolipidemic 
effect of estrogen, appearing both m female and male type III 
HLP patients, is the result of an improved catabolism of VLDL-
remnants, particularly by direct degradation, presumably in the 
liver, and not by conversion to LDL. In contrast to normal sub­
jects and type IV HLP patients estrogen has no appreciable effect 
on the turnover rate of VLDL-TG in type III HLP. 
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Type III hyperlipoproteïnemie, ook wel familiaire dysbeta-
lipoproteïnemie, broad-beta-disease of floating-beta-disease 
genaamd, is een familiaire stoornis in het lipoproteïnen-
metabolisme. De ziekte is gekenmerkt door een verhoging van 
zowel het serumcholesterol als de serumtriglycenden, het voor-
komen van Xanthomen en een sterke predispositie voor athero-
sclerotische complicaties van coronaire en perifere artenën. 
Klinische verschijnselen. Tussen 1956 en 1980 werden 39 
patiënten (27 mannen en 12 vrouwen) met deze vorm van HLP m 
ons ziekenhuis behandeld (hoofdstuk 2). Van hen waren 4 bi] 
familie-onderzoek ontdekt. Slechts 3 patiënten werden wegens 
verhoogde plasmalipidenspiegels verwezen. Ongeveer de helft van 
de patiënten was naar onze afdeling verwezen wegens de gevolgen 
van de hyperlipidemie: 11 patiënten met Xanthomen, 7 met athero-
sclerotisch vaatlijden. Veertien patiënten waren om andere 
redenen verwezen en bij hen werd de hyperlipidemie bij toeval 
ontdekt; dit was vooral het geval m de laatste 5 jaar. 
B13 deze ziekte komen twee soorten Xanthomen frequent voor: 
de palmaire Xanthomen (handlijnxanthomen), geel oranje vetdepo-
sities in de handlijnen, pathognomonisch voor dit ziektebeeld, 
en de tubero-eruptive Xanthomen, ontsierende en soms invalide-
rende knobbels op ellebogen, knieën, billen en handen. Beide 
soorten kwamen bij ongeveer de helft van onze patiënten voor. 
Xanthelasmata en peesxanthomen worden uiterst zelden gezien bij 
type III hyperlipoproteïnemie, in tegenstelling tot de bevin-
dingen bij familiaire hypercholesterolemie. 
Bij 22 van onze 39 patiënten werden atherosclerotische 
complicaties vastgesteld: 15 hadden evidente klachten van angina 
pectoris of hadden een myocardinfarct doorgemaakt, 18 patiënten 
hadden tekenen van perifeer vaatlijden. Geen van onze patiënten 
had symptomen van cerebro-vasculair lijden. Er is dus een sterke 
predispositie voor hart-vaatlijden, waarbij opvalt dat de coro-
naire en perifere artenën even sterk betrokken worden, in tegen-
stelling tot familiaire hypercholesterolemie, waarbij alleen de 
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kans op coronairli^den is toegenomen. 
Bij de mannen manifesteerde de ziekte zich eerder dan bij de 
vrouwen (resp. gemiddeld 40 en 55 jaar). Hetzelfde gold voor het 
moment waarop voor het eerst Xanthomen (resp. 37 en 55 jaar) en 
vaatlijden (resp. 47 en 56 jaar) werden vastgesteld. Bij 10 van 
de 12 vrouwen openbaarde de hyperlipidemie zich pas na de meno-
pauze; dit wordt verklaard door het lipidenverlagende effect van 
oestrogenen bij deze ziekte. De diagnose wordt uiterst zelden 
bij kinderen gesteld. De jongste patiënt in onze serie was een 
man van 29 jaar. 
Geen van onze patiënten had een klinische diabetes mellitus 
op het moment van het stellen van de diagnose. Herkenning van 
hypothyreoïdie is belangrijk, temeer omdat substitutie met 
schildklierhormoon een sterke daling van de serumlipiden geeft, 
zoals bij 2 van onze patiënten wordt geïllustreerd. 
Diagnose. De bevestiging van de diagnose vereist moderne 
ingewikkelde laboratoriumtechnieken. De diagnose is gebaseerd 
op drie afwijkende kenmerken van de very low density lipopro-
te'inen (VLDL) fractie, die geïsoleerd wordt uit het plasma met 
behulp van de ultracentrifuge: 
- de afwezigheid van het apolipoproteïne (аро)Е-З 
- een hoog cholesterolgehalte, blijkens een ratio tussen VLDL-
cholesterol en serumtriglycenden (in mmol/1) van meer dan 
0,69 en een ratio tussen VLDL-cholesterol en VLDL-triglyceri-
den van meer dan 0,92. 
- een lagere mobiliteit dan normaal bij electrophorese op aga­
rose. 
De veranderde samenstelling van de VLDL-fractie is een ge­
volg van de toegenomen hoeveelheid VLDL-remnants (zie Patho­
genese) , die zich voor het grootste deel in de VLDL-fractie 
bevinden. Aangezien deze remnants in vergelijking met normaal 
VLDL relatief cholesterolnjk zijn, heeft de VLDL-fractie een 
relatief hoog cholesterolgehalte. De veranderde mobiliteit bij 
electrophorese op agarose kan worden verklaard door de lagere 
mobiliteit van VLDL-remnants ten opzichte van normaal VLDL. 
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Overerving. De wijze van overerving is lange tijd onzeker 
geweest. De ontdekking van apoE-3 deficiëntie bij type III 
patiënten gaf de sleutel tot de oplossing. Het apoE-3 gehalte in 
de VLDL blijkt te worden bepaald door twee co-dominante allelen. 
Er zijn drie fenotypen mogelijk: apoE-N (normaal apoE-3 gehalte), 
apoE-ND (intermediair gehalte), apoE-D (ernstig tekort of com-
plete afwezigheid van apoE-3). In West-Duitsland en Noord-
Amerika wordt de frequentie van deze fenotypen m de bevolking 
geschat op resp. 84, 15 en 1%. Slechts 1 à 4° van de personen 
met fenotype E-D hebben echter ook een hyperlipoproteïnemie, en 
wel uitsluitend type III. De factoren die bijdragen tot de ont-
wikkeling van verhoogde serumlipiden bij deze personen, worden 
besproken bij de Pathogenese. 
Wij onderzochten 108 familieleden (93 eerste graads) van 20 
type III patiënten (hoofdstuk 3). Achtenveertig van hen hadden 
een hyperlipidemie. Vijf werden geclassificeerd als type II, 8 
als type III en 35 als type IV. De meesten wisten niet dat ze 
verhoogde serumlipiden hadden. Type III hyperlipoproteïnemie 
werd gevonden bij 7 broers en zussen en 1 neef. Zij hadden allen 
fenotype apoE-D. Daarnaast waren er 5 familieleden met fenotype 
apoE-D zonder HLP. Zij hadden waarschijnlijk (nog?) geen ver-
hoogde serumlipiden omdat zij relatief mager dan wel premeno-
pausaal waren. De wijze van overerving van het apoE-fenotype 
geschiedde in alle onderzochte families volgens een autosomaal 
recessieve wijze. Natuurlijk is verticale transmissie van feno-
type apoE-D mogelijk, zeker gezien de relatief hoge frequentie 
van fenotype apoE-ND in de bevolking. Inderdaad heeft één van 
onze type III patiënten, die gehuwd is met een heterozygoot, 
een kind met fenotype apoE-D. 
Het is nog niet zeker of fenotype apoE-ND stoornissen geeft 
m het lipoprotelnenmetabolisme. De frequentie van hyperlipide-
mie onder de door ons onderzochte familieleden met de verschil-
lende fenotypen was ongeveer gelijk: 45% bij fenotype apoE-N, 
44% bij apoE-ND en 62% bij apoE-D. Het gehalte aan cholesterol 
m de VLDL-fractie was bij personen met fenotype apoE-ND even 
hoog als bij fenotype apoE-N. Er zijn dus geen aanwijzingen voor 
een toegenomen aantal VLDL-remnants. 
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Familie-onderzoek bij type III patiënten is geïndiceerd 
wegens de hoge prevalentie van hyperlipidemie. Type III hyper-
lipoproteïnemie zal meestal alleen bi] broers en zussen gevonden 
worden. Verder onderzoek moet uitwi]zen of herkenning van feno-
type apoE-D bij normolipemici van belang is wegens de kans op 
het ontwikkelen van type III hyperlipoproteïnemie. Fenotype 
apoE-ND lijkt tot dusver niet van klinisch belang. 
Therapie. De uitstekende reactie van type III hyperlipopro-
teïnemie op therapie is bevredigend voor zowel de patiënt als de 
behandelend arts. De behandeling bestaat allereerst uit dieet, 
meestal alleen caloriebeperkt. Veel type III patiënten hebben 
een overgewicht, zoals ook m onze serie. Maar ook patiënten met 
een vrijwel ideaal gewicht reageren gunstig op een gewichts-
daling van enkele kilo's. Wanneer met dieet alleen de daling van 
de serumlipiden onvoldoende is, kan de behandeling worden uit-
gebreid met het medicament clofibraat. Met een dosis van 2 maal 
daags ^ à 1 gram worden de lipidenwaarden vaak normaal. 
In een retrospectief onderzoek (hoofdstuk 4) bestudeerden 
wij het effect van clofibraat bij 9 ernstige type III patiënten, 
die het middel gedurende tenminste 7 jaar gebruikten. Het gemid-
delde serumcholesterolgehalte daalde van 14,3+4,4 tijdens dieet 
tot 8,5+3,2 nunol/l tijdens clofibraat. De gemiddelde serumtn-
glyceridenspiegel daalde van 5,6+1,9 tot 2,9+0,8 mmol/1. Dit 
effect hield gedurende de gehele follow-up periode van 7 tot 9 
jaar aan ondanks een geringe gewichtsstijging. Ernstige bij-
werkingen werden niet waargenomen. In de loop van deze behan-
deling, na 3 tot 8 jaar gebruik, werd het middel bij alle patiën-
ten tijdelijk gestaakt. Bij allen stegen de lipidenwaarden tot 
de uitgangswaarden. Deze gegevens duiden erop dat clofibraat voor 
type III hyperlipoproteïnemie een waardevol, sterk lipidenver-
lagend medicament is, dat zijn werkzaamheid behoudt ook na vele 
jaren gebruik. Behandeling van type III hyperlipoproteïnemie 
doet Xanthomen na enkele maanden verdwijnen, doch er zijn nog 
onvoldoende objectieve gegevens om zeker te zijn van een ver-
mindering van de kans op atherosclerotische complicaties. 
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Pathogenese. VLDL, die worden gesynthetiseerd in de lever 
als triglyceridennjke partikels, worden omgezet tot cholesterol-
njke low density lipoproteïnen (LDL), via een tussenproduct, de 
VLDL-remnants. Normaal zíjn VLDL-remnants nauwelijks in het plas-
ma aantoonbaar omdat ze zeer snel omgezet worden. In geval van 
type III hyperlipoproteïnemie bestaat er een overmaat van VLDL-
remnants. Het is aannemelijk dat er een stoornis in de klaring 
van VLDL-remnants bestaat. Aangezien het apoproteïne E betrokken 
is bij de afbraak van VLDL-remnants door interactie met apoE-
receptoren op de hepatocyten-membraan, wordt gedacht dat het 
gebrek aan apoE-3 aan dit klaringsdefect bi] type III patiënten 
ten grondslag ligt. 
Infusie van donorplasma met een normaal apoE-3 gehalte bij 
een type III patiënt zou het ontbrekende apoproteïne zodanig 
kunnen suppleren, dat het klaringsdefect zou worden opgeheven. 
Deze hypothese werd opgesteld naar analogie van het opmerkelijk 
triglycenden verlagende effect van donorplasma bij een patiënt 
met familiaire hyperchylomicronemie op basis van apoproteïne 
C-II deficiëntie. ApoC-II is de activator van lipoproteïnelipase, 
dat de afbraak van triglycendenrijke deeltjes reguleert. Het 
geinfundeerde plasma suppleerde blijkbaar het ontbrekende apoC-II. 
Bij de type III patiënt bleek echter geen daling van de serum-
lipidenspiegels op te treden (hoofdstuk 5). Evenmin veranderde 
de samenstelling van de VLDL-fractie. Blijkbaar speelt apoE-3 
niet dezelfde kritische rol bij de afbraak van lipoproteïnen 
als apoC-II. 
Naast een klaringsdefect kan ook een toegenomen productie 
van VLDL een rol spelen in de Pathogenese, door oververzadiging 
van het normale klaringsmechanisme. Teneinde een indruk te krij-
gen over de grootte van de VLDL-productie hebben wij de turnover-
snelheid van VLDL-triglycenden gemeten met de radioglycerol-
methode bij 7 type III patiënten en de resultaten vergeleken met 
een controlegroep en een groep type IV patiënten met dezelfde 
gemiddelde triglycendenspiegel. De gemiddelde turnoversnelheid 
bij de type III patiënten was significant hoger dan die bij de 
normalen en gelijk aan die bij de type IV groep (hoofdstuk 6). 
Deze gegevens passen in de veronderstelling dat personen met 
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een gebrek aan apoE-3 een klaringsdefect van VLDL-remnants heb-
ben zonder dat dit hoeft te leiden tot hyperlipidemia. Als er 
een factor bijkomt, die de VLDL-productie doet toenemen, zal 
type III hyperlipoproteinemie kunnen optreden. Dit kunnen gene-
tische factoren zijn, zoals familiaire predispositie voor hyper-
lipoproteinemie of verworven factoren als overgewicht, hypothy-
reoïdie, verminderde glucosetolerantie en overmatig alcohol-
gebruik . 
Werkingsmechanisme van clofibraat. De werking van clofi-
braat wordt toegeschreven aan diverse mechanismen o.a. afname 
van de productie van tnglyceriden in de lever, toename van de 
klaring van tnglyceriden en toename van de lipolytische acti-
viteit. Vrijwel alle onderzoeken werden verricht bij controle-
personen of type IV patiënten. Wij bestudeerden de invloed van 
clofibraat op de turnoversnelheid van VLDL-tnglyceriden bij 4 
type III patiënten (hoofdstuk 7). Bij allen bleek deze te dalen 
tot normale of hoog-normale waarden. Met deze meting kan geen 
inzicht worden verkregen in de omzetting van VLDL-remnants. In 
de eerste week van behandeling met clofibraat zagen wij bij alle 
9 onderzochte patiënten echter een voorbijgaande stijging van 
LDL-cholesterol, hetgeen moet worden verklaard door een toege-
nomen omzetting van VLDL-remnants tot LDL. 
Werkingsmechanisme van oestrogenen. Toediening van oestro-
genen aan normolipemisrhe personen en type IV patiënten leidt 
tot verhoging van de serumtnglyceriden, als gevolg van een 
toename van de triglycendenproductie in de lever. Bij patiënten 
met type III hyperlipoproteinemie treedt juist een sterke 
lipidendalmg op, hetgeen verklaart dat bij vrouwen de ziekte 
zich pas na de menopauze manifesteert. Tijdens toediening van 
oestrogenen verdwijnen volgens mededelingen in de literatuur 
ook de type III kenmerken als de cholesterolnjkdom van de VLDL-
fractie en de ß-VLDL. Wij gingen op dezelfde wijze als met 
clofibraat na hoe de werking van oestrogenen tot stand komt 
(hoofdstuk 8). Vier patiënten (2 mannen en 2 postmenopausale 
vrouwen) met type III HLP werden gedurende 15 dagen met lage 
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dosis oestrogenen behandeld. Bij allen werden de lipidenwaarden 
vrijwel geheel normaal. De productiesnelheid van VLDL-triglyce-
riden veranderde niet. Dit betekent dat de verlaging van de 
serumlipiden tot stand moet zijn gekomen door een toegenomen 
klaring van VLDL-remnants. Indien deze VLDL-remnants tot LDL 
worden omgezet, dan zou tijdens de eerste dagen van oestrogenen-
gebruik een stijging van LDL-cholesterol gezien moeten worden 
zoals bij clofibraat. Aangezien dit niet werd waargenomen, moet 
worden verondersteld dat de VLDL-remnants direct afgebroken zijn, 
mogelijk in de lever. Om te weten hoe dit precies plaatsvindt, 
is nader onderzoek vereist. Een mogelijke verklaring zou correc-
tie van het apoE-3 tekort kunnen zijn; doch dit defect blijft 
tijdens de oestrogenenbehandelmg bestaan. 
Algemene conclusie voor de medische praktijk. Het is van 
belang type III hyperlipoproteïnemie te herkennen en te onder-
scheiden van andere vormen van hyperlipoproteïnemie. Het betreft 
namelijk een aandoening, die gepaard gaat met een sterke kans op 
coronair en perifeer vaatlijden, die goed toegankelijk is voor 
therapie, ook op lange termijn. De definitieve diagnose vereist 
ingewikkeld laboratoriumonderzoek, doch op klinische gronden kan 
deze sterk vermoed worden: de typische palmaire Xanthomen, de 
verhoging van zowel de cholesterol- als de triglyceridenspiegel 
bij patiënten met perifeer vaatlijden op relatief jonge leeftijd, 
of een sterke variabiliteit van de serumlipiden. Aangezien het 
een erfelijke aandoening betreft en er een hoge prevalentie van 
hyperlipoproteïnemie (vooral type IV, minder type II en III) 
onder familieleden is, is familie-onderzoek geïndiceerd. 
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WOORDEN VAN WAARDERING 
Allen die hebben bijgedragen aan de totstandkoming van dit 
proefschrift wil ik gaarne bedanken. 
De verpleegkundigen van de algemene interne polikliniek 
waren behulpzaam bi} het verzamelen van de vele bloedmonsters. 
Hun begeleiding van de patiënten bij de dikwijls langdurige 
experimenten zijn mede een waarborg geweest voor het slagen 
van deze onderzoeken. 
Riky Vos-Janssen, Anneke Hijmans en Dea van Sommeren-
Zondag hebben grote steun gegeven aan het opzetten van vele 
ingewikkelde laboratoriumtechnieken. Talloze bloedmonsters 
werden door hen nauwgezet geanalyseerd. 
Het typewerk werd verzorgd door Manet Beurskens. 
De tekeningen voor dit proefschrift werden met zorg ver-
vaardigd door de heer J. Konings van de afdeling Medische 
Illustratie en gefotografeerd door medewerkers van de afdeling 
Medische Fotografie. 
De staf van de Medische Bibliotheek was behulpzaam bij het 
verzamelen van de literatuur. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd geboren op 16 maart 1948 
te Muiden. Hl] bezocht het Geert Grootte College te Deventer en 
het Sint Janslyceum te 's-Hertogenbosch en behaalde het eind­
diploma gymnasium β in 19b6. Vervolgens studeerde hij genees­
kunde aan de Katholieke Universiteit te Nijmegen, waar hij in 
1971 het doctoraalexamen en m 1974 het artsexamen aflegde. In 
de Universiteitskliniek voor Inwendige Ziekten te Nijmegen 
(destijds hoofd: Prof. Dr. C.L.H. Majoor) werd hij opgeleid tot 
internist. Op 15 maart 1979 werd hij ingeschreven in het specia-
listenregister. Vanaf 1979 is hij werkzaam op de afdeling alge­
mene interne geneeskunde (hoofd: Prof. Dr. A. van 't Laar) van 
de Universiteitskliniek voor Inwendige Ziekten te Nijmegen. 
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STELLINGEN 
behorende bij het proefschrift 
CLINICAL AND METABOLIC STUDIES IN 
TYPE III HYPERLIPOPROTEINEMIA 
in het openbaar te verdedigen op 
vrijdag 15 januari 1982 des 
namiddags te 2 uur precies 
door 
P.M.J. Stuyt 
1 
Naast een stoornis in de afbraak van "remnants" van very low 
density lipoproteïnen (VLDL) speelt overproductie van VLDL-
triglycenden een rol bij de Pathogenese van type III hyper-
lipoproteïnemie. 
- dit proefschrift 
2 
Bij een vrouw voor de menopauze met verhoogde serumlipiden-
spiegels is de diagnose type III hyperlipoproteïnemie vrijwel 
uitgesloten. 
- dit proefschrift 
3 
Bij miskenning van de diagnose type III hyperlipoproteïnemie is 
de kans groot dat een patiënt een eenvoudige, op de lange duur 
bevredigende behandeling onthouden wordt, en dat hi] een groot 
risico op atherosclerotische complicaties houdt. 
- dit proefschrift 
4 
Bepaling van het apolipoproteïne E fenotype is alleen zinvol bij 
een vermoeden van de diagnose type III hyperlipoproteïnemie en 
bij onderzoek van familieleden van type III patiënten. 
- dit proefschrift 
- Stuyt PMJ, Stalenhoef AFH, Demacker PNM, Van 't Laar A, 
ongepubliceerd onderzoek 
5 
Aan de WHO-clofibraattrial wordt ten onrechte de conclusie 
ontleend dat clofibraat carcinogeen zou zijn. 
- Committee of Principal Investigators 
Br Heart J 1978; 40· 1069-1118, Lancet 1980; 2 379-385 
6 
De waarde van nicotmezuur als serumlipidenverlagend medicament 
dient opnieuw bepaald te worden, nu is gebleken dat de hinder­
lijke flushes voorkomen kunnen worden met een lage dosis acetyl-
salicylzuur. 
- Illingworth RI, Phillipson BE, Rapp JII , Connor WE, Lancet 
1981 , 1 : 296-298 
- Kane JP, Malloy MJ, Tun Ρ, Phillips NR, Freedman DD, Williams 
ML, Rowe JS, Havel RJ, N Engl J Med 1981, 304- 251-256 
7 
Een verhoogde alkalische fosfatase-activiteit in het serum bij 
een patiënt met klachten die zouden kunnen wijzen op een poly-
myalgia rheumatica, kan deze diagnose steunen en hoeft geen re-
den te zijn het onderzoek in een andere richting uit te breiden. 
- Von Knorring J, Wasastjerna C, Scan J Rheumatology 1976; 5: 
197-204 
- eigen waarneming 
8 
Bij bloedingen in het bovenste gedeelte van de tractus digesti-
vus is een acute oesophago-gastroscopie niet routinematig ge-
ïndiceerd . 
- Peterson WL, Barnett CC, Smith HJ, Allen MH, Corbett DB, 
N Engl J Med 1901, 304 925-929 
9 
Aangezien de talloze laboratoriumproeven een veel groter aan-
deel hebben m de groei van de kosten van de gezondheidszorg 
dan de toepassing van zeer kostbare apparatuur bi] diagnostiek 
en behandeling, moet in het kader van bezuiniging meer aandacht 
worden besteed aan het beperkt, selectief gebruik van deze 
onderzoeken. 
- Moloney TW, Rogers DE, N Engl J Med 1979; 301 1413-1419 
10 
Patiënten met een maligne aandoening mogen alleen met cytosta-
tica behandeld worden indien door onderzoek een gunstig effect 
van de behandeling op het beloop van de ziekte en op de kwali-
teit van het leven is aangetoond, of indien de behandeling wordt 
gegeven in het kader van een gecontroleerde studie. 
11 
Bi] de moderne op het verkeersaanbod reagerende verkeerslicht-
installaties hebben voor fietsers detectielussen de voorkeur 
boven drukknoppen. 
12 
De opkomst van het verschijnsel groepsprakti^k is relatief laat 
te noemen wanneer men in aanmerking neemt dat de samenwerkende 
artsen en tweelingbroers HH. Cosmas en Damianus reeds vanaf de 
5e eeuw als patronen van de medische stand vereerd worden; 
verwonderlijk is deze aarzeling tot navolging echter niet wan-
neer men hun bijnaam άνάργυροι beschouwt welke duidt op het 
weigeren van honorarium. 


